

# Marc-André Gagnon (PhD), Associate Professor

---

School of Public Policy & Administration  
Carleton University  
1125 Colonel By Drive (RB-5224)  
Ottawa, Ontario (Canada)  
K1S 5B6

Cross appointed with the Institute of  
Political Economy, Carleton University

Phone: (613) 520-2600 x1690  
Fax : (613) 520-2551  
E-mail: ma.gagnon@carleton.ca

---

## Research Interests

Social and Health Policy

Political Economy

Sociology of Science and Technology

Pharmaceutical Policy and Regulation

Innovation policy

History of Economic and Political Thought

---

## **A. EDUCATION**

- York University: PhD in Political Science; Major in *Political Theory* 2009  
Dissertation: *The Nature of Capital in the Knowledge-Based Economy; The Case of the Global Pharmaceutical Industry.*
- Ecole Normale Supérieure Fontenay/St-Cloud and Université Paris-I (Sorbonne): 2001  
Master of Advanced Studies in History of Economic Thought, Mention  
Dissertation: *Controverses américaines sur la nature et la mesure du capital; la contribution de Thorstein Veblen.*
- Université du Québec à Montréal: MA Political Science, with Honors 2000  
Thesis: *Penser l'économie par la métaphore biologique.*
- Université du Québec à Montréal : Certificate in Economics 1997
- Université du Québec à Montréal: B.A. in Political Science 1996

## Post-Doctoral Research

- Harvard University: Post-Doctoral Research at the Edmond J. Safra Center for Ethics 2010-2012  
under the supervision of Lawrence Lessig; Topic: *The Political Economy of Pharmaceutical Corruption.*
- McGill University: Post-Doctoral Research at the Faculty of Law with the Center for 2009-2010  
Intellectual Property Policy under the supervision of Richard Gold; Topic: *Words and Numbers Determining Pharmaceutical Investments; Financialization and the Extension of Intellectual Property Rights.*

## Contents

|  |    |
|--|----|
| A. EDUCATION .....   | 1  |
| Post-Doctoral Research .....   | 1  |
| B. OTHER RESEARCH EMPLOYMENT AND AFFILIATION .....                   | 3  |
| C. AWARDS AND HONORS .....   | 4  |
| D. PUBLICATIONS .....  | 4  |
| 1-REFEREED SCHOLARLY PUBLICATIONS .....                              | 4  |
| Articles in refereed journals .....                                  | 4  |
| Articles submitted for publication in peer-reviewed journals .....   | 6  |
| Chapters in edited books .....                                       | 6  |
| 2-OTHER (NON-REFEREED) SCHOLARLY PUBLICATIONS .....                  | 7  |
| Articles in non-refereed journals .....                              | 7  |
| Chapters in non-refereed books .....                                 | 7  |
| Technical reports .....  | 9  |
| Book reviews in scholarly journals.....                              | 10 |
| Research Papers .....  | 10 |
| 3-PROFESSIONAL PUBLICATIONS .....                                    | 11 |
| E. OTHER SCHOLARLY AND PROFESSIONAL ACTIVITY .....                   | 16 |
| 2. PRESENTATIONS AND CONTRIBUTIONS .....                             | 16 |
| -Presentations at Scientific Conferences .....                       | 16 |
| -Other Presentations, Seminars and Conferences (on invitation) ..... | 18 |
| 3. RESEARCH GRANTS AND RESEARCH CONTRACTS .....                      | 26 |
| 4. OTHER PROFESSIONAL ACTIVITIES .....                               | 27 |
| Peer-Reviews: .....  | 27 |
| Service to the Profession: .....                                     | 28 |
| F. ACADEMIC RESPONSIBILITIES .....                                   | 29 |
| TEACHING AND ACADEMIC EXPERIENCE .....                               | 29 |
| Visiting Professor .....   | 29 |
| Graduate courses taught .....  | 29 |
| Undergraduate courses taught .....                                   | 29 |
| SUPERVISION AND EXAMINATION OF DISSERTATIONS .....                   | 30 |
| Supervisions completed .....   | 30 |
| Supervisions in progress .....                                       | 31 |
| G. ADMINISTRATIVE RESPONSIBILITIES AT CARLETON UNIVERSITY .....      | 32 |
| H. OTHER.....  | 34 |
| KNOWLEDGE TRANSLATION ACTIVITIES AND PUBLIC POLICY MEETINGS .....    | 34 |
| MAJOR RADIO AND TV INTERVIEWS .....                                  | 39 |

## B. OTHER RESEARCH EMPLOYMENT AND AFFILIATION

|  |           |
|--|-----------|
| Fellow with the WHO Collaborating Centre for Governance, Accountability and Transparency in the Pharmaceutical Sector  | 2016-...  |
| Co-lead and researcher for the Rational Therapeutics and Medication Policy Research group  | 2015-...  |
| Adjunct Member with the Graduate Program in Health, Faculty of Graduate Studies, (York University, Toronto)  | 2014-...  |
| Mentor for Drug Safety and Effectiveness Cross-Disciplinary Training Program. Training Program established by Canadian Institutes for Health Research.   | 2013-...  |
| Research fellow with <i>Centre d'études sur l'intégration et la mondialisation</i> (UQAM)  | 2012- ... |
| Expert on healthcare policy for the <i>EvidenceNetwork.ca</i> .  | 2011- ... |
| Adjunct Researcher for <i>Institut de Recherches et d'Informations Socio-économiques</i>   | 2010- ... |
| Visiting Professor at University of Ottawa, Centre for Health Law, Policy and Ethics   | 2016-2017 |
| Research fellow with the <i>Pharmaceutical Policy Research Collaboration</i>   | 2009-2015 |
| Visiting Professor, Université Montesquieu Bordeaux-IV, GREThA Lab   | 2014      |
| Research fellow for the <i>Edmond J. Safra Center for Ethics, Harvard University</i>   | 2010-2013 |
| Columnist for <i>Protégez-Vous</i> .   | 2010-2012 |
| Adjunct Researcher for <i>Institut d'Études Internationales de Montréal</i>  | 2006-2012 |
| Researcher for <i>Chaire Mondialisation, Citoyenneté et Démocratie</i> , UQAM<br>Research for CAFCA project on Financialization in Advanced Capitalism<br>Historical analysis of income inequality in the United States.                               | 2006-2009 |
| Researcher for the project <i>Études sur les Technologies de l'Information et des Communications</i> of <i>Centre Études Internationales et Mondialisation</i> (UQAM)<br>Analysis of firms "intangible assets" as a measure of control over knowledge. | 2003-2006 |
| Research Assistant for <i>Groupe de recherches en pratiques et politiques statistiques</i> , UQAM<br>Analysis of international networks in statistical organizations 1885-1914.  | 1997-1999 |

## C. AWARDS AND HONORS

|   |      |
|---|------|
| Public Commentary Award, Faculty of Public Affairs, Carleton University (\$1,000)   | 2015 |
| Ethel Meade Award for Excellence in Healthcare Research, from Ontario Health Coalition  | 2014 |
| “Rising Star Award” from the Institute of Health Services and Policy Research (\$1,000) for knowledge translation initiative on dominant pharmaceutical business model. | 2010 |
| Yumiko Iida Memorial PhD Prize for best dissertation in political science (\$500)   | 2010 |
| Excellence Award by the Union of Lecturers at University of Montreal  | 2008 |
| Excellence Award from the <i>Association des cadres de l’UQAM</i> (1,000\$)   | 1997 |
| Excellence Award in Political Science, UQAM for highest academic standing (1,000\$)   | 1996 |
| Award of <i>Fonds Interculturel UQAM</i> for helping improving intercultural relations (2,000\$)  | 1995 |

## D. PUBLICATIONS

### *1-REFEREED SCHOLARLY PUBLICATIONS*

#### Articles in refereed journals

**Gagnon, Marc-André**, 2015. “The role and impact of cost-sharing mechanisms for prescription drug coverage”. *Canadian Medical Association Journal* 189 (19): E680-E681.

Morgan, Steven G., **Marc-André Gagnon**, Barbara Mintzes and Joel Lexchin, 2016. “A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada”. *Healthcare Policy* 12 (1), May 2016.

**Gagnon, Marc-André**, 2015. “New Drug Pricing; Does it make any sense?” *Prescrire International* 24 (162): 192-195. English translation of **Gagnon, Marc-André**, 2015. « Pourquoi les médicaments sont-ils si chers? Les dérives d’un modèle d’affaires. » *Prescrire* 35 (380): 457-461.

O’Brady, Sean, **Marc-André Gagnon** and Alan Cassels, 2015. « Reforming Private Drug Coverage in Canada; Inefficient Drug Benefit Design and the Barriers to Change in Unionized Settings ». *Health Policy*, Vol. 119 #2, February 2015: 224-31.

**Gagnon, Marc-André** (principal author) and Dimitri della Faille, 2014. “Thorstein Veblen: Économiste Iconoclaste.” *European Journal of Economic and Social Systems*. Vol. 26 #1-2, 2014: 11-30.

Prémont, Marie-Claude and **Marc-André Gagnon**, 2014. « Trois types de stratégies de fidélisation des fabricants de médicaments novateurs ». *Healthcare Policy* Vol. 10 #2, November 2014: 79-89.

- Lexchin, Joel and **Marc-André Gagnon**, 2014. « CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs ». *Globalization and Health*, Vol. 10 #30, May 2014.
- Gagnon, Marc-André**, 2013. "Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health," in *Journal of Law, Medicine and Ethics*, Vol. 41 #3, September 2013: 571-580. (Impact Factor: 1.169)
- Gagnon, Marc-André**, 2012. "Corporate influence over clinical research: Considering the alternatives." *Prescrire International* 21(129): 191-194. English translation of **Gagnon, Marc-André**, 2012. "Recherche Clinique Sous Influence: Penser les Alternatives." *Prescrire* (342) (March 2012): 311-314.
- Gagnon, Marc-André**, 2012. "Drug Shortages: Searching for a Cure." *Healthcare Policy* 7(4): 10-17. (Impact Factor: 0.582)
- Gagnon, Marc-André**, 2012. "L'Aide Publique à L'Industrie Pharmaceutique Québécoise: le jeu en vaut-il la Chandelle?" *Interventions Économiques/Papers in Political Economy* (44): 1-17.
- Gagnon, Marc-André**, 2011. "Marx's Social Analysis of Value and Big Pharma: Rethinking the Social Determinants of Value in Cognitive Capitalism." *European Journal of Economic and Social Systems* 24 (1-2): 119-136.
- Gagnon, Marc-André**, 2008. "Le Modèle de Croissance Anglo-Saxon en Théorie et en Pratique: Analyse du Régime de Croissance Américain." *Cahiers de Recherche Sociologique* (45): 93-111.
- Gagnon, Marc-André** (principal author) and Joel Lexchin, 2008. "The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States." *PLoS Medicine* 5(1): 1-6. (Impact Factor: 16.27)
- Gagnon, Marc-André**, 2007. "Capital, Power & Knowledge according to Thorstein Veblen: Reinterpreting the Knowledge-Based Economy." *Journal of Economic Issues* 41(2): 593-600. (Impact Factor: 0.32)
- Gagnon, Marc-André**, 2007. "Penser le Capitalisme Cognitif selon Thorstein Veblen: Connaissance, Pouvoir & Capital." *Interventions Économiques* (36) : 1-21.
- Gagnon, Marc-André** (principal author) and Dimitri della Faille, 2007. "La Sociologie Économique de Thorstein Veblen: Pertinences et Impertinences d'une Pensée à Contre-courant." *Interventions Économiques* (36): 1-13.
- Gagnon, Marc-André** (principal author) and Dimitri della Faille, 2007. "Héritage de Veblen et Nouvelles Perspectives pour les Sciences Sociales." *Interventions Économiques* (36): 1-12.
- Gagnon, Marc-André**, 1999. "Frank Zappa: Présentation d'un Intellectuel Spécifique." *Conjonctures* (29): 118-145.

### Articles submitted for publication in peer-reviewed journals

**Gagnon, Marc-André** (principal author) and Karena Volesky. “Merger Mania: Mergers and acquisitions in the generic drug sector from 1995 to 2016”. Paper accepted for publication for publication in *Globalization and Health*.

Morgan, Steve, **Marc-Andre Gagnon**, Alain Vadeboncoeur, Mathieu Charbonneau. “Evaluating the effects of Quebec’s public-private drug insurance system”. Paper accepted for publication in *Canadian Medical Association Journal*.

Charbonneau, Mathieu, **Marc-Andre Gagnon**. “Surviving niche busters: main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs”. Paper submitted for publication to *Health Policy*.

### Chapters in edited books

**Gagnon, Marc-André**, 2016. “Shaping the social determinants of value through economic ghostmanagement: an institutionalist approach to capital accumulation.” Published in Tae-Hee Jo and Frederic S. Lee (eds). *Marx, Veblen, and the Foundations of Heterodox Economics: Essays in Honor of John F. Henry*. London and New York: Routledge.

**Gagnon, Marc-André** (principal author) and Dimitri della Faille, 2013. “Thorstein Veblen: Economista Iconoclasta.” Published in P.P. Poggio (dir.) *L'altronovecento. Comunismo eretico e pensiero critico*. Vol 3: *Il Capitalismo Americano E I Suoi Critici*. Milano: Jaca Book.

**Gagnon, Marc-André**, 2012. “Les Droits de Propriété Intellectuelle sont-ils un écueil pour la modernité industrielle? La cas des brevets dans l’industrie pharmaceutique” in Marie-Pierre Boucher (dir.) *La Propriété et ses Multiples*. Montreal : Nota Bene: 201-250.

**Gagnon, Marc-André**, 2004. “La main visible de la propriété intellectuelle contre l’intérêt général: Les formes disciplinaires du néolibéralisme,” in *La Régulation Néolibérale: Crise ou ajustement?* Edited by Raphael Canet and Jules Duchastel. Montreal: Athéna Éditions; pp.175-200.

**Gagnon, Marc-André**, 2002. “Mercantilisme,” in *Relations Internationales: Théories et Concepts*. Ed. Évelyne Dufault, Guillaume Dufour, and Alex MacLeod. Montréal: Athéna Éditions; 128-130.

**Gagnon, Marc-André**, 2000. “Les réseaux de l’internationalisme statistique (1885-1914),” in Jean-Pierre Beaud and Jean-Guy Prévost (dir.) *L’ère des chiffres: systèmes statistiques et traditions nationales*. Québec: Presses de l’Université du Québec; 181-220.

## **2-OTHER (NON-REFEREED) SCHOLARLY PUBLICATIONS**

### **Articles in non-refereed journals**

**Gagnon, Marc-André**, 2014. « Le rôle essentiel de la recherche publique en santé ». *Les Nouveaux Cahiers du Socialisme*. Vol. 12, Fall 2014.

**Gagnon, Marc-André**, 2012. “Point of View: Bulk Purchasing of Drugs.” *The Medical Post*. <http://www.canadianhealthcarenetwork.ca/physicians/discussions/point-of-view/bulk-purchasing-of-drugs> . Reprinted as well in *Pharmacy Practice, Nurse Newslines and Canadian Healthcare Manager*.

**Gagnon, Marc-André** and Sergio Sismondo, 2010. “The Ghosts of Medical Research.” *Genetic Engineering and Biotechnology News* 30(10).

Biron, Pierre (principal author), **Marc-André Gagnon**, Joel Lexchin, James M. Wright, Adam Hoffman and Vijaya Musini, 2009. “Is the Diovantage Patient Support Program Direct-to-Consumer Advertising?” *Canadian Journal of Clinical Pharmacology* 16(2): 285-286. (Non-refereed comment in refereed journal). (Impact Factor: 0.788)

**Gagnon, Marc-André** and Joel Lexchin, 2008. “Study Authors Assail Column as the Real Flawed Thinking.” *Medical Post*.

**Gagnon, Marc-André**, 2008. “Patients Shortchanged by Big Pharma.” *Genetic Engineering and Biotechnology News* 28(4).

**Gagnon, Marc-André**, 2007. “La théorie de l’accumulation différentielle: analyser le capital en tant que pouvoir social.” *Le Cahier de l’ACSALF: Critique du Capitalisme Avancé* 4(1).

### **Chapters in non-refereed books**

**Marc-Andre Gagnon**, 2016. “Provincial Health Ministers right to push for national pharmacare program –but what kind?”, in Noralou Roos, Kathleen O’Grady, Eileen Boriskewich, Mélanie Meloche-Holubowski, Carolyn Shimmin, Kristy Wittmeier and Nanci Armstrong (eds). *Why We Need More Canadian Health Policy in the Media*. Winnipeg: EvidenceNetwork.ca: pp.288-290.

Cassels, Alan, Sean O’Brady and **Marc-Andre Gagnon**, 2016. “Why Employers in Canada Waste \$5 Billion a Year on Inefficient Drug Coverage?”, in Noralou Roos, Kathleen O’Grady, Eileen Boriskewich, Mélanie Meloche-Holubowski, Carolyn Shimmin, Kristy Wittmeier and Nanci Armstrong (eds). *Why We Need More Canadian Health Policy in the Media*. Winnipeg: EvidenceNetwork.ca: pp.291-293.

**Marc-André Gagnon**, 2015. “How a national drug plan can boost the Canadian economy”, in Noralou Roos, Kathleen O’Grady, Camilla Tapp, Shannon Turczak and Lindsay Jolivet (eds). *Navigating the Evidence; Communicating Canadian Health Policy in the Media*. Winnipeg: EvidenceNetwork.ca: pp.256-257.

- Marc-André Gagnon**, 2015. “Comment un régime d’assurance-médicaments national relancerait l’économie canadienne”, in Noralou Roos, Kathleen O’Grady, Camilla Tapp, Shannon Turczak and Lindsay Jolivet (eds). *Navigating the Evidence; Communicating Canadian Health Policy in the Media*. Winnipeg: EvidenceNetwork.ca: pp.258-260.
- Marc-André Gagnon**, 2014. “Who’s afraid of Universal Pharmacare”, in Noralou Roos, Kathleen O’Grady, Camilla Tapp, Shannon Turczak and Lindsay Jolivet (eds). *Making Evidence Matter in Canadian Health Policy*. Winnipeg: EvidenceNetwork.ca: pp.103-105.
- Marc-André Gagnon** (principal author) et Guillaume Lamy. “Accroître la protection par brevet permet d’accroître l’innovation” in Guillaume Lamy (ed.) *C’est encore faux; 50 idées déconstruites par des spécialistes*. Montréal : Éditions du Septentrion. Septembre 2013.
- Marc-André Gagnon** (principal author) et Guillaume Lamy. “La recherche privée est plus utile que la recherche publique” in Guillaume Lamy (ed.) *C’est encore faux; 50 idées déconstruites par des spécialistes*. Montréal : Éditions du Septentrion. Septembre 2013.
- Gagnon, Marc-André**, 2012. “Pharmacare and Federal Drug Expenditures: A Prescription for Change,” in *How Ottawa Spends 2012-2013: The Harper Majority, Budget Cuts, and the New Opposition*, edited by G Bruce Doern and Christopher Stoney, 161-172. Toronto: McGill-Queens University Press.
- Gagnon, Marc-André**, 2012 “Provinces must stand together on drug purchases”, in Noralou Roos, Sharon Manson Singer, Kathleen O’Grady, Camilla Tapp, Shannon Turczak (eds). *Canadian Health Policy in the News; Why Evidence Matters*. Winnipeg: EvidenceNetwork.ca: pp.111-113.
- Gagnon, Marc-André**, 2012 “Patent protection for brand-name drugs should come at a price”, in Noralou Roos, Sharon Manson Singer, Kathleen O’Grady, Camilla Tapp, Shannon Turczak (eds). *Canadian Health Policy in the News; Why Evidence Matters*. Winnipeg: EvidenceNetwork.ca: pp.126-131.
- Gagnon, Marc-André**, 2012 “Our broken drug plan; Inefficient, costly and inequitable”, in Noralou Roos, Sharon Manson Singer, Kathleen O’Grady, Camilla Tapp, Shannon Turczak (eds). *Canadian Health Policy in the News; Why Evidence Matters*. Winnipeg: EvidenceNetwork.ca: pp.139-141.
- Gagnon, Marc-André**, 2012 “How Canada artificially inflates the cost of prescription drugs to the tune of \$2 billions”, in Noralou Roos, Sharon Manson Singer, Kathleen O’Grady, Camilla Tapp, Shannon Turczak (eds). *Canadian Health Policy in the News; Why Evidence Matters*. Winnipeg: EvidenceNetwork.ca: pp.142-146.
- Gagnon, Marc-André** (principal author) and Sergio Sismondo, 2012. “Beware the ghosts of medical research: How Big Pharma has developed new forms of ‘research’ to serve their interests”, in Noralou Roos, Sharon Manson Singer, Kathleen O’Grady, Camilla Tapp, Shannon Turczak (eds). *Canadian Health Policy in the News; Why Evidence Matters*. Winnipeg: EvidenceNetwork.ca: pp.147-153.
- Gagnon, Marc-André**, 2012 «Quelle stratégie québécoise pour l’accès aux médicaments », in Noralou Roos, Sharon Manson Singer, Kathleen O’Grady, Camilla Tapp, Shannon Turczak (eds). *Canadian Health Policy in the News; Why Evidence Matters*. Winnipeg: EvidenceNetwork.ca: pp.174-176.



**Gagnon, Marc-André**, 2011. “L’industrie pharmaceutique au Québec.” in L’Institut du Nouveau Monde. *État du Québec 2011*. Montréal : Boréal; 294-296.

### **Technical reports and Policy Briefs**

**Marc-André Gagnon**. *Commentaires quant aux modifications proposées au règlement sur les médicaments brevetés*. Memoir Submitted to Health Canada, June 2017.

**Marc-André Gagnon**. *Propositions quant à la modernisation réglementaire du conseil d’examen des prix des médicaments; Comment trouver l’équilibre nécessaire contre les prix excessifs dans un secteur pharmaceutique en mutation*. Memoir submitted to the Patented Policy Price Review Board’s Regulatory Modernization. October 2016.

**Marc-André Gagnon**. *Financing the Public Provision of Prescription Drugs in Canada: Comparison and Assessment of Financing Options*. Internal Report prepared for Health Canada. June 2016.

**Marc-André Gagnon**. *Informations complémentaires quant à la mise en place d’un régime national d’assurance-médicaments*. Memoir submitted to the Standing Committee on Health of the House of Commons, Government of Canada. April 8 2016.

**Marc-André Gagnon**. *Informations complémentaires quant au projet de loi 81 (Loi visant à réduire le coût de certains médicaments couverts par le régime général d’assurance médicaments en permettant le recours à une procédure d’appel d’offres)*. Memoir submitted to Commission de la santé et des services sociaux, Quebec National Assembly. March 2016 :  
[http://www.assnat.qc.ca/Media/Process.aspx?MediaId=ANQ.Vigie.Bll.DocumentGenerique\\_111977&process=Default&token=ZyMoxNwUn8ikQ+TRKYwPCjWrKwg+vIv9rjjj7p3xLGTZDmLVSmJLoqe/vG7/YWzz](http://www.assnat.qc.ca/Media/Process.aspx?MediaId=ANQ.Vigie.Bll.DocumentGenerique_111977&process=Default&token=ZyMoxNwUn8ikQ+TRKYwPCjWrKwg+vIv9rjjj7p3xLGTZDmLVSmJLoqe/vG7/YWzz)

**Marc-André Gagnon** (principal author) and Sidney Wolfe. 2015. *Mirror, Mirror on the Wall: Medicare Part D pays needlessly high brand-name drug prices compared with other OECD countries and with U.S. government programs*. Report for Public Citizen and Carleton University’s School of Public Policy and Administration. Policy Brief, July 23 2015.

Steven G. Morgan, Danielle Martin, **Marc-André Gagnon**, Barbara Mintzes, Jamie R. Daw and Joel Lexchin. 2015. *Pharmacare 2020; The Future of Drug Coverage in Canada*. Published by the Pharmaceutical Policy Research Collaboration, University of British Columbia. July 15 2015.

**Marc-André Gagnon**. *A Roadmap to Rational Pharmacare Policy in Canada*. Ottawa: Canadian Federation of Nurses Unions. August 2014:  
[https://nursesunions.ca/sites/default/files/pharmacare\\_report.pdf](https://nursesunions.ca/sites/default/files/pharmacare_report.pdf)

Marie-Claude Prémont and **Marc-André Gagnon**. *Les nouvelles stratégies commerciales de maximisation des ventes des fabricants de médicaments novateurs*. Internal Report prepared for Ordre des pharmaciens du Québec. March 10, 2014.

**Marc-André Gagnon** (principal author) and Joel Lexchin. *CETA and Pharmaceuticals: Impact of the free-trade agreement between Europe and Canada on the costs of patented drugs*. Study

published by the Canadian Center for Policy Alternatives. October 31 2013:  
<https://www.policyalternatives.ca/publications/reports/ceta-and-pharmaceuticals>

**Marc-André Gagnon** (principal author) and Joel Lexchin. *CETA and Intellectual Property: The Debate over Pharmaceutical Patents*. Policy Brief for the Canada-Europe Transatlantic Dialogue, CETA Policy Briefs Series. October 2013: [http://labs.carleton.ca/canadaeurope/wp-content/uploads/sites/9/CETD-Policy-Brief\\_CETA-and-pharmaceutical-patents\\_MG\\_JL.pdf](http://labs.carleton.ca/canadaeurope/wp-content/uploads/sites/9/CETD-Policy-Brief_CETA-and-pharmaceutical-patents_MG_JL.pdf)

**Marc-André Gagnon** (principal author) and Richard Gold. *Public Financial Support to the Canadian Brand-name Pharmaceutical Sector: A Cost-Benefit Analysis*. Internal report commissioned by Health Canada. March 2011.

**Marc-André Gagnon** (principal author) and Guillaume Hébert. “The Economic Case for Universal Pharmacare.” Ottawa: IRIS and CCPA, September 2010: [pharmacarenow.ca](http://pharmacarenow.ca).

Morgan, Steve (principal author), **Marc-André Gagnon**, Michael Law, et al. “Pharmaceutical Industry Employment in Canada: Levels, Trends and Issues for Consideration” Internal report commissioned by Health Canada and produced by *Pharmaceutical Policy Research Collaboration*, March 2010 (Published in August 2010):  
[http://chspr.ubc.ca/sites/default/files/publication\\_files/PPRC\\_Employment\\_in\\_Canada\\_2010.pdf](http://chspr.ubc.ca/sites/default/files/publication_files/PPRC_Employment_in_Canada_2010.pdf)

Gold, Richard (principal author), Tania Bubela, Julia Carbone, **Marc-André Gagnon** and Yann Joly. “At the Intersection of Health and Intellectual Property: Issues, Tools and Directions for Health Canada.” Internal report commissioned for Health Canada by *The Innovation Partnership*, March, 2010:  
<http://www.theinnovationpartnership.org/data/documents/00000023-1.pdf>

### **Book reviews in scholarly journals**

**Gagnon, Marc-André**, 2011. Review of *Médicaments: de la conception à la prescription* (Catherine Garnier and Joseph Lévy, Montréal: Liber, 2009). *Recherches Sociographiques* 52(1).

**Gagnon, Marc-André**, 2007. Review of *In Plain English: A Complete Introduction to Thorstein Veblen’s Economics* (Ken McCormick, Youngstown: Cambria Press, 2006) *Interventions Économiques* (36).

### **Research Papers**

*Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health*. Edmond J. Safra Center for Ethics, Harvard University, June 2013:  
[http://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=2286415](http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2286415)

*Compétitivité et croissance économique aux États-Unis: Cui Bono?*, Note de recherches Observatoire des Amériques, UQAM, 2005.

*Nouvelle Économie et Actifs Intangibles: Les défis de la dimension immatérielle de la création de valeur*, GRIC Research Paper, UQAM, 2004.

*Piétinement des négociations des ADPIC et l'accès aux médicaments essentiels à l'approche de la Conférence ministérielle de Cancun*, Observatoire des Amériques, UQAM, 2003.

*TRIPS and Pharmaceuticals; Inquiry into the Foundations of the International Political Economy of Intellectual Property Rights*, GRIC Research Paper, UQAM, 2002.

### **3-PROFESSIONAL PUBLICATIONS (op-eds and commentaries)**

**Marc-André Gagnon**, 2017. « Comment réduire le coût des médicaments génériques? » *Le Devoir*. 14 juillet 2017 : <http://www.ledevoir.com/societe/sante/503427/comment-reduire-le-cout-des-medicaments-generiques>

**Marc-André Gagnon**, 2017. “Why Free Drug Plans for the Wealthy –And Poor- are good”. *Ottawa Citizen*. May 18 2017: <http://ottawacitizen.com/opinion/columnists/gagnon-why-free-drugs-for-the-wealthy-and-poor-is-good-policy>

**Marc-André Gagnon**, 2015. “Federal Elections and Prescription Drugs; A Grade Report.” Blog entry for *Policy Options* : <http://policyoptions.irpp.org/2015/10/17/federal-elections-and-prescription-drugs-a-grade-report/>

**Marc-André Gagnon**, 2015. « Élections et médicaments; Bilan de campagne ». *Le Devoir*. 15 octobre 2015 : <http://www.ledevoir.com/politique/canada/452574/elections-et-medicaments-bilan-de-campagne>

**Marc-André Gagnon**, 2015. “Quebec should not be the model for national pharmacare.” *Globe and Mail*, June 26 2015: <http://www.theglobeandmail.com/opinion/quebec-should-not-be-the-model-for-national-pharmacare/article25135678/> Also published in the Huffington Post and as a blog entry for *Policy Options*.

**Marc-André Gagnon**, 2015. “Comment réduire le coût des médicaments au Québec”, Blog entry for *Policy Options* : <http://policyoptions.irpp.org/2015/04/17/how-to-reduce-drug-costs-in-quebec/>. A version of this commentary also appeared in *La Presse* : <http://www.lapresse.ca/debats/votre-opinion/201504/17/01-4862118-des-factures-abusives.php> and in Huffington Post: [http://quebec.huffingtonpost.ca/marcandre-gagnon/cout-medicaments-quebec\\_b\\_7128776.html](http://quebec.huffingtonpost.ca/marcandre-gagnon/cout-medicaments-quebec_b_7128776.html)

Alan Cassels, Sean O’Brady and **Marc-André Gagnon**, 2014. “Why employers in Canada waste \$5 billion a year on inefficient drug coverage”. A version of this commentary appeared in the *Montréal Gazette*, the *Vancouver Sun* and the *Huffington Post*: <http://umanitoba.ca/outreach/evidencenetwork/archives/23310#sthash.FSCo0vIS.dpuf>

**Gagnon, Marc-André**, 2014. “L’assurance-médicaments relancerait l’économie.” *Le Droit*. December 8 2014: <http://www.lapresse.ca/le-droit/opinions/votre-opinion/201412/08/01-4826233-lassurance-medicaments-relancerait-leconomie.php>

- Gagnon, Marc-André**, 2014. “A national drug plan in Canada could boost the economy.” *Toronto Star*. August 18 2014:  
[http://www.thestar.com/opinion/commentary/2014/08/18/a\\_national\\_drug\\_plan\\_in\\_canada\\_could\\_boost\\_the\\_economy.html](http://www.thestar.com/opinion/commentary/2014/08/18/a_national_drug_plan_in_canada_could_boost_the_economy.html)
- Gagnon, Marc-André**, 2013. “What my critics don’t get about drug policy.” *Huffington Post*. July 3 2013: [http://www.huffingtonpost.ca/marcandre-gagnon/drug-policy-canada\\_b\\_3536203.html](http://www.huffingtonpost.ca/marcandre-gagnon/drug-policy-canada_b_3536203.html)
- Gagnon, Marc-André**, 2013. “How a Canadian Drug Plan would Benefit Canadians.” *Huffington Post*. June 12 2013: [http://www.huffingtonpost.ca/marcandre-gagnon/canada-national-drug-plan\\_b\\_3430031.html](http://www.huffingtonpost.ca/marcandre-gagnon/canada-national-drug-plan_b_3430031.html)
- Gagnon, Marc-André**, 2013. “The Case for National Pharmacare.” *National Post*. June 10 2013: <http://fullcomment.nationalpost.com/2013/06/10/marc-andre-gagnon-the-case-for-national-pharmacare/>
- Gagnon, Marc-André**, 2012. “The Op-Ed: Canada, Patents and Corporate Welfare.” *Pharmalot*, November 27 2012: <http://www.pharmalot.com/2012/11/the-op-ed-canada-patents-corporate-welfare/>
- Gagnon, Marc-André** (principal author) et David Hughes, 2013. “Un cadeau coûteux pour les Québécois.” *La Presse*, November 23 2012: <http://www.lapresse.ca/debats/votre-opinion/2012/11/23/01-4596761-un-cadeau-couteux-pour-les-quebecois.php>
- Gagnon, Marc-André**, 2012. “Des auteurs fantômes discréditent la recherche médicale.” *Le Soleil*. October 2 2012 : <http://www.lapresse.ca/le-soleil/opinions/points-de-vue/2012/10/01-4579239-des-auteurs-fantomes-discreditent-la-recherche-medicale.php>
- Gagnon, Marc-André**, 2012. “Pour éviter une hausse de prix des médicaments.” *Le Droit*, September 19 2012 : <http://www.lapresse.ca/le-droit/opinions/votre-opinion/2012/09/19/01-4575403-pour-eviter-une-hausse-du-prix-des-medicaments.php>
- Gagnon, Marc-André**, 2012. “Libre-échange Canada-Europe et les médicaments.” *L’aut’ Journal*. <http://www.lautjournal.info/default.aspx?page=3&NewsId=3980>.
- Gagnon, Marc-André**, 2012. “Patent Protection Should Come at a Price.” *Winnipeg Free Press*. <http://www.winnipegfreepress.com/opinion/westview/patent-protection-for-drugs-should-come-at-a-price-167652895.html>. Reprinted as well in Troy Media, Guelph Mercury and Waterloo Record.
- Gagnon, Marc-André**, 2012. “Provinces Must Stand Together on Drug Purchases.” *The Globe and Mail*. <http://www.theglobeandmail.com/commentary/provinces-must-stand-together-on-drug-purchases/article4450319/> .
- Gagnon, Marc-André** and Saul Schwartz, 2012. “Government said No to a Legitimate Tax Credit.” *Montreal Gazette*. <http://www.montrealgazette.com/business/Opinion+Government+said+legitimate+credit+idea/7019910/story.html#ixzz26jevywit>.

- Gagnon, Marc-André** and Saul Schwartz, 2012. "Tuition Fees and Tax Credits: Are the Québec Students Right?" *One Page Policy Blog*. <http://saulschwartz.com/2012/07/08/tuition-fees-and-tax-credits-are-the-quebec-students-right/>.
- Gagnon, Marc-André**, 2012. "R&D: Le Gouffre Financier." *À Babord*.
- Gagnon, Marc-André**, 2012. "Détournement de Cause." *Protégez-Vous*. <http://www.protegez-vous.ca/affaires-et-societe/detournement-de-cause.html>.
- Gagnon, Marc-André**, 2011. "Malaise Générique." *Protégez-Vous*. <http://www.protegez-vous.ca/sante-et-alimentation/malaise-generique.html>.
- Gagnon, Marc-André**, (28 octobre 2011) "Regards sur la CAQ: Une Bonne Note Pour la Politique sur les Médicaments." *Institut de Recherches et d'Informations Socio-économique*. <http://www.iris-recherche.qc.ca/blogue/regards-sur-la-caq-une-bonne-note-pour-la-politique-sur-les-medicaments/>
- Gagnon, Marc-André**, 2011. "Mourir sur Ordonnance." *Protégez-Vous*. <http://www.protegez-vous.ca/sante-et-alimentation/mourir-sur-ordonnance.html>.
- Gagnon, Marc-André**, 2011. "Beware the Ghostwriters of Medical Research." *Times and Transcript*. <http://timestranscript.canadaeast.com/opinion/article/1418736> ; and *Troy Media*. <http://www.troymedia.com/2011/06/16/beware-the-ghostwriters-of-medical-research/>.
- Gagnon, Marc-André**, 2011. "Why our prescription drugs are too expensive and what we can do about it", in *HuffPost Canada*. [http://www.huffingtonpost.ca/marcandre-gagnon/prescription-drug-costs\\_b\\_877024.html](http://www.huffingtonpost.ca/marcandre-gagnon/prescription-drug-costs_b_877024.html).
- Gagnon, Marc-André**, 2011. "Des ententes secrètes nuisibles." *Protégez-Vous*. <http://www.protegez-vous.ca/sante-et-alimentation/ententes-secretes-nuisibles.html>.
- Gagnon, Marc-André**, 2011. "Is Drug Research Turning into a Scam?" *The Mark*. <http://www.themarknews.com/articles/5110-is-drug-research-turning-into-a-scam>.
- Gagnon, Marc-André**, 2011. "Médicaments: Un Gaspillage Annuel de Deux Milliards." *Cyberpresse.ca*. <http://www.cyberpresse.ca/le-soleil/opinions/points-de-vue/201104/21/01-4392303-medicaments-un-gaspillage-annuel-de-deux-milliards.php>.
- Gagnon, Marc-André**, 2011. "Pourquoi Payons-nous Si Cher les Médicaments?" *Protégez-Vous*. <http://www.protegez-vous.ca/sante-et-alimentation/pourquoi-medicaments-sont-chers.html>.
- Gagnon, Marc-André**, 2011. "Canada can cut Rx Drug Costs." *Telegraph Journal*. <http://telegraphjournal.canadaeast.com/opinion/article/1400883>.
- Gagnon, Marc-André**. 2011. "Our Surprisingly Expensive Pharmaceuticals." Op-ed *The Mark*. <http://www.themarknews.com/articles/4789-our-surprisingly-expensive-pharmaceuticals>.
- Gagnon, Marc-André**, 2011. " Why Our Prescription Drugs are Too Expensive and What We Can Do About It." *Troy Media*. <http://www.troymedia.com/2011/04/13/why-our-prescription-drugs-are-too-expensive-and-what-we-can-do-about-it/>.

- Gagnon, Marc-André**, 2011. “Why the System is Broken.” Op-ed *The Montréal Gazette*. <http://www.montrealgazette.com/health/system+broken/4639165/story.html>; and *The Edmonton Journal*. <http://www.edmontonjournal.com/health/system+broken/4639165/story.html>.
- Gagnon, Marc-André**, 2011. “Pour un Régime D’Assurance-Médicaments Public et Universel.” *Protégez-Vous*. <http://www.protegez-vous.ca/sante-et-alimentation/pour-un-regime-d-assurance-medicaments-public-et-universel.html>.
- Gagnon, Marc-André**, 2011. “The \$2-billion Extra Price Tag of Brand-Name Drugs in Canada”. Op-ed *The Hill Times*. <http://www.thehilltimes.ca/page/view/brandname-02-07-2011>.
- Gagnon, Marc-André**, 2010. “Why Canadians Need Universal Pharmacare.” Op-ed *Winnipeg Free Press*. <http://www.winnipegfreepress.com/opinion/westview/why-canadians-need-universal-pharmacare-105014014.html>.
- Gagnon, Marc-André**, 2010. “Why Canadians Need Universal Pharmacare.” Op-ed *Chronicle Herald*.
- Gagnon, Marc-André**, 2010. “Un Régime Universel Public Pour Tous les Québécois.” Op-ed *Cyberpresse*. <http://www.cyberpresse.ca/opinions/201009/17/01-4316658-medicaments-un-regime-universel-public-pour-tous-les-quebecois.php>.
- Gagnon, Marc-André**, 2010. “The Pros and Cons of Universal Pharmacare.” Op-ed *Vancouver Sun*. <http://www.vancouver.sun.com/opinion/pros+cons+universal+Pharmacare/3532240/story.html>.
- Gagnon, Marc-André**, 2010. “À Quand Un Régime Public Universel D’Assurance Médicaments au Québec?” *Relations* (743).
- Gagnon, Marc-André**, 2010. “L’industrie pharmaceutique et la recherche publique en santé.” *Relations* (738).
- Gagnon, Marc-André**, 2009. “Recherche Médicale: La Belle Affaire!” *Le Devoir*.
- Gagnon, Marc-André**, 2009. “La Crise Actuelle: Les Leçons du Passé.” *Relations* (733).
- Gagnon, Marc-André**, 2009. “Relancer L’Économie...Oui, Mais Dans Quelle Direction?” *Bulletin de la Ligue des Droits et Libertés*.
- Gagnon, Marc-André**, 2009. “La ‘fausse classe moyenne’ piégée.” *Journal Alternatives* 15(8).
- Poirier, Daphnée, and **Marc-André Gagnon**, 2009. “Consommation de Médicaments—La Légèreté Outrancière du Ministre Bolduc.” *Le Devoir*.
- Gagnon, Marc-André**, 2008. “Contre la Privatisation des Savoirs.” *Relations* (729).
- Gagnon, Marc-André**, 2008. “Crise de la Finance et Détresse des Démunis.” *Relations* (726).
- Gagnon, Marc-André**, 2008. “The Other Crisis of US Capitalism.” *Le Panoptique* (30).
- Gagnon, Marc-André**, 2008. “Penser L’Économie Autrement.” *Relations* (724).

**Gagnon, Marc-André**, 2008. “Une Pratique Répandue: Quand la Promotion des Médicaments se Fait au Détriment de la Santé Publique.” *La Presse*: A-23.

**Gagnon, Marc-André**, 2008. “The Vioxx Affair, Symptom of an Industry’s Disease.” *Le Panoptique* (21).

**Gagnon, Marc-André** (principal author) and Thomas Chiasson Lebel, 2007. “Retour sur L’Investissement en Éducation.” *Relations* (721).

**Gagnon, Marc-André**, 2005. “Un Québec Lucide au Sujet du Capitalisme du XXIe Siècle,” *Le Devoir*.

**Gagnon, Marc-André**, 2005. “Les Marchands de Chandelle Contre la Grande Bibliothèque.” *Le Devoir*.

**Gagnon, Marc-André**, 2004. “Fiscalité—Le Québec Doit-il Favoriser les Riches? L’Institut Économique de Montréal Base ses Arguments sur des Dogmes Rétrogrades.” *Le Devoir*.

## E. OTHER SCHOLARLY AND PROFESSIONAL ACTIVITY

### 2. PRESENTATIONS AND CONTRIBUTIONS

#### -Presentations at Scientific Conferences

- August 19 2017 (Quebec City): « *L'économie politique fantôme des firmes pharmaceutiques: Analyser les racines du surdiagnostic* ». Presentation at the Preventing Overdiagnosis Conference, Quebec Convention Center.
- April 24 2017 (Ottawa): With Karena Volesky: "Mergers and Acquisitions in the Generic Drug sector: The impacts of this forgotten factor on pricing and shortages". Presentation at the Canadian Agency for Drugs and Technology of Health Conference 2017, Shaw Centre.
- November 28 2016 (Toronto): "Tackling the Corruption of Pharmaceutical Markets: Addressing the Misalignment Between Financial Incentives and Public Health". Symposium Combating Corruption in Health Care and Pharmaceuticals. Munk School of Global Affairs, University of Toronto.
- May 28 2015 (Montreal). Marc-André Gagnon, Sean O'Brady, and Alan Cassels. "Reforming Private Drug Coverage in Canada: Inefficient Benefit Design and the Barriers to Change in Unionized Settings", Canadian Association for Health Services and Policy Research (CAHSPR) Conference 2015.
- May 1-2 2015 (Cambridge, Boston): "Seven categories of ghostmanagement; Rethinking capital accumulation in the biopharmaceutical sector". Poster presentation for the *Ending Institutional Corruption Conference*, organized by the Edmond J. Safra Center for Ethics, at Harvard Law School.
- July 22 2014 (Montreal): "Prescription Drug Costs in Canada: Why Such an Awful Record in Terms of Cost-Containment?" Panel: Health Expenditure and Cost Control: Why Some Nations Do Better than Others. International Political Science Association Conference, Palais des Congrès.
- July 2 2014 (Paris, France): « Corruption institutionnelle dans le secteur bio-pharmaceutique; Comprendre l'économie politique de l'influence ». Colloque de l'Association Française d'Économie Politique, Panel: Politiques industrielles. École Normale Supérieure de Cachan.
- May 13 2014 (Toronto): "Containing Costs ≠ Passing the Buck". Sub-plenary panel: *Policy Imperatives for Pharmaceutical Coverage and the Role of Pricing*. Conference of Canadian Association for Health Services and Policy Research (CAHSPR) 2014.
- November 29 2013 (Ottawa): "The Canadian Pharmaceutical Sector: From Knowledge-based Economy to Corporate Welfare". Presentation for the conference *Corporate Welfare; Public Policies for Private Corporations*. Institute of Political Economy, Carleton University.



- July 4 2013 (Bordeaux, France): “Le marché du médicament au Canada; Protection Sociale vs Innovation.” Colloque de l’Association Française d’Économie Politique, Panel: Marchandisation de la santé et protection sociale. Université Montesquieu Bordeaux-IV.
- May 25 2013 (Ottawa): “Un régime public universel pour améliorer l’accès et réduire les coûts en médicaments; Une approche pragmatique.” *Rethinking Drug Coverage in Canada; Is it time for Universal Pharmacare?* Organized by the *School of Public Policy And Administration at Carleton University*, and by the *Canadian HealthCoalition*. Hotel National, May 24-25 2013: <http://www1.webcastcanada.ca/online/archives/pharmacare/day2-2-eng/index.php>
- February 26 2013 (Vancouver): “Access and Costs for Prescription Drugs; Is it Time for Canada to Enter the 21<sup>st</sup> Century?” Conference *Pharmacare 2020; Envisioning Canada’s Future*, organized by the *Pharmaceutical Policy Research Collaboration* and the *Center for Health Services and Policy Research (UBC)*. Sheraton Wall Centre.
- February 21 2013 (Washington D.C.): “Clinical Trials in the Age of Corporate Science: What should be the role of public research?” *Selling Sickness Conference 2013; People Before Profit*. Hyatt Regency Washington on Capitol Hill.
- May 29-31, 2012 (Montreal): « Le régime québécois d’assurance-médicaments : un modèle à la dérive ». Sub-plenary panel: *Drug Insurance in Quebec: Model or Foil*. Conference of *Canadian Association for Health Services and Policy Research (CAHSPR) 2012*.
- May 24 2012 (Ottawa): « The Evolving Business of the Global Pharmaceutical Industry ». Presentation for the Conference *Global Governance for Health: Perspectives from Canada*, organized by *Carleton University* and the *Norwegian Embassy*.
- October 20-21 2011 (Toronto): « Veblenian Analysis of Big Pharma’s Intangible Assets: Capitalizing Medical Bias ». Conference *The Capitalist Mode of Power: Past, Present , Future*. *Second Annual Forum on Capital as Power*, *York University*.
- May 9 2011 (Sherbrooke): « Les aides au secteur biopharmaceutique : un coût d’opportunité économiquement irrationnel ». Conference *Une autre science est possible : science collaborative, science ouverte, science engagée, contre la marchandisation du savoir*. *ACFAS 2011*.
- April 15 2011 (Magog-Orford): « Le modèle économique des entreprises de recherche pharmaceutique ». *Les pharmaceutiques, le médecin et son patient*. Hotel Cheribourg. Organized by the *Centre de formation continue de la Faculté de médecine de l’Université de Sherbrooke*.
- November 29 2010 (Toronto): “Drug Promotion: Costs and Impact on Medical Practice”. *To Do No Harm Conference*. Four Seasons Hotel.
- October 21 2010 (Montreal): « Opportunity Cost: An Estimate of Public Subsidies to Biopharmaceutical R&D in Canada ». *Canadian Science Policy Conference*.
- “Opportunity Cost: An estimate of Public Subsidies to biopharmaceutical R&D in Canada”. Conference of *Canadian Association for Health Services and Policy Research (CAHSPR)*, Toronto, May 2010.
- “Veblenian Analysis of Big Pharma’s Intangible Assets: Capitalizing Medical Bias.” Presentation for *Association for Institutional Thought*. *Western Social Science Association Conference*, Reno (Nevada), April 2010.
- “Définir et dominer: La science comme champ de bataille.” Colloque étudiant annuel de sociologie. *Les avancées de la technoscience : Risques ou progrès?* April 2010.

- “Pharmaceutical Innovation and Promotion in a Global Marketplace: Understanding Big Pharma’s Strategies.” Faculty of Medicine/Faculty of Law Annual Colloquium: *Universities as Global Innovators*, February 2010.
- “Le capitalisme des origines confronté au capitalisme avancé; essai de réconciliation” Conference *Sociologie historique et transition(s) au(x) capitalisme(s)*, ACFAS, Ottawa, May 2009.
- “La rentabilité des médicaments d’aujourd’hui finance-t-elle les miracles de demain?”, Presentation for the 2e Congrès international du GEIRSO, Montreal, October 2007.
- “Le droit international comme stratégie corporative”, Conference *Le rôle du droit dans les relations internationales* (ACFAS), Trois-Rivières, May 2007.
- “Compétitivité et croissance économique aux États-Unis”, Conference *Sens des inégalités contemporaines et la question des classes sociales* (ACFAS), Trois-Rivières, May 2007.
- “Structural Competition in the Global Pharmaceutical Business”, Conference *Rethinking Capitalist Power*, UMASS in Amherst, October 2006.
- “Financialization as Differential Accumulation: The Case of Pharmaceuticals”, Conference of the *Canadian Economic Association*, Concordia University, May 2006.
- “L’impérialisme est mort. Vive l’Empire? Appropriation des savoirs & domination post-coloniale”, Conference *L’impérialisme dans la Mondialisation* (ACFAS), Chicoutimi, 2005.
- “Les droits de propriété intellectuelle dans la Nouvelle Économie”, Conference *Perspectives sur le néolibéralisme* (ACFAS), Rimouski, 2003.
- "Les approches rivales en histoire de la pensée économique", Conference *Le Politique et les Idées; Approches, Théories, Méthodes*, UQAM, February 2003.
- "La construction morale du concept de capital chez Adam Smith", CRESP Conference, *Formes et lieux de pouvoir*, UQAM, February 15-16 2002.
- “Internationalisme statistique (1885-1914); une analyse de réseaux”, International Conference *Internationalisme statistique, pratiques étatiques & traditions nationales*, UQAM, 1999.

### **-Other Presentations, Seminars and Conferences (on invitation)**

- April 22 2017 (Banff): “Rx Drugs in the 21st Century: Price, Access and Regulation in an era of Unsustainable Costs”. Keynote presentation for the Canadian Association of Pharmacy in Oncology Conference 2017, The Fairmont Banff Springs Hotel.
- April 11 2017 (Ottawa): “We can afford universal drug coverage in Canada; Policy Imperatives and political challenges in reforming Pharmaceutical Coverage in Canada”. Presentation for the Conference A Prescription for Equity; A National Public Drug Plan for All, Organized by the Canadian Health Coalition, Delta Hotel.
- March 20 2017 (Ottawa): “The future of drug coverage in Canada; Policy imperatives and political challenges in reforming pharmaceutical coverage in Canada”. Presentation for Health Law course given by Colleen Flood, University of Ottawa.

- March 1 2017 (Milano, Italy) : “From Blockbusters to Nichebusters: Regulatory challenges with high-priced specialty drugs”. Presentation for Istituto di Ricerche Farmacologiche Mario Negri, Milano.
- November 10 2016 (Montreal): « Débat sur la désinformation scientifique ». Cœur des Sciences, UQAM.
- October 25 2016 (Ottawa): “How can Australia’s Experience Inform the Architecture of Pharmacare?”. Presentation and discussion for the Centre for Health Law, Policy and Ethics, University of Ottawa.
- October 24 2016 (Ottawa) : “CETA and TPP: Impact on the Canadian Pharmaceutical Sector”. Presentation for the Center for Law, Technology and Society Lecture Series: Trans-Pacific Partnership, Intellectual Property and Health; What’s at Stake? University of Ottawa.
- June 12 2016 (Ottawa): « Nos médicaments nous en donnent-ils pour notre argent? Prix et régulation en France et au Canada ». Presentation for *Société des Amis Canada-France*.
- June 9 2016 (Toronto): “Rx Drugs in the XXIst Century: Price, Access, Regulation, Coverage and Appropriate Use”. Keynote presentation for the Graduate Research in Progress (GRIP) Annual Conference, Leslie Dan Faculty of Pharmacy, University of Toronto.
- April 29 2016 (Toronto): “Disclosure of conflicts of interests and transparency in drug pricing”. Presentation for WHO Collaborating Centre for Governance, Accountability and Transparency in the Pharmaceutical Sector, University of Toronto.
- April 27 2016 (Toronto): “New Drug Pricing and Regulation; Does it make any sense?”. Presentation for Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) Annual symposium. Double-Tree by Hilton.
- March 24 2016 (Ottawa): “A new era of information in decision making; The battlefield of evidence-based policy”. FPA Research Month closing panel. River Building, Carleton University.
- March 21 2016 (Ottawa): “The future of drug coverage in Canada; Policy imperatives and political challenges in reforming pharmaceutical coverage in Canada”. Presentation for Health Law course given by Colleen Flood, University of Ottawa.
- February 26 2016 (Ottawa): “How a national drug plan could improve appropriateness for prescription drugs”. Presentation for the Conference: “How to ensure appropriate and safe use of Medications in Canada?” Organized by the Rational Therapeutics and Medication Research Group during Carleton University’s Faculty of Public Affairs Research Month. Carleton University, Ottawa.
- January 19 2016 (Ottawa): “CETA and TPP: Impact on the Canadian Pharmaceutical Sector”. Presentation for the Conference *Positioning Canada to be a Leader in the Global IP System* organized by CIGI International Law Research Program. Westin Hotel.
- November 26 2015 (Ottawa): “How should a National Drug Plan Look?”. Presentation for Research in Progress Rounds, C.T. Lamont Primary Health Care Research Centre, Bruyère Hospital.

- November 13 2015 (Halifax): “Impact of CETA on intellectual property for prescription drugs in Canada”. Presentation for the workshop *CETA on the brink: Post-Election Politics and the Finalization of the Canada-EU Deal*. Dalhousie University’s European Union Centre of Excellence.
- November 3 2015 (Ottawa): Presentation on the legal aspects of drug coverage reforms for a graduate course in health law given by Martha Jackman. University of Ottawa.
- October 13 2015 (Toronto): Presentation on how universal pharmacare could improve prescribing habits for a graduate course in pharmaceutical policy given by Nancy Olivieri and Elia Abi-Jaoude. University of Toronto.
- October 9 2015 (Ottawa): Presentation on Canadian Health Insurance for graduate course in social policy given by Geranda Notten. University of Ottawa.
- October 5 2015 (Pan-Canadian webinar): “A Roadmap to a Rational Pharmacare Policy in Canada”. Webinar presentation for Neighborhood Pharmacies Association of Canada.
- September 21 2015. (St-Marc-sur Richelieu, Quebec) : « Un régime public universel d’assurance-médicaments pour le Québec; Comment réconcilier accès, équité et efficacité ». Présentation pour l’Ordre des Pharmaciens du Québec. Auberge des Trois Tilleuls.
- June 8 2015 (Toronto): “Mirror, Mirror on the Wall; Lessons learned from other jurisdictions.” Presentation for Minister’s Roundtable on Pan-Canadian Pharmacare. Sheraton Center Toronto Hotel. **8 Provincial Health Ministers attended the presentation.**
- May 27 2015 (Montreal): « Le Transfert de connaissances dans les médias: Un casse-tête nécessaire ». Panel: Interdépendance entre chercheurs et journalistes: Défis, pièges et bonnes pratiques, organisé par Chaire de Recherche -Politiques Connaissances et Santé de l’Université de Montréal, Grande Bibliothèque de Montréal.
- April 24 2015 (Quebec City): Expert Roundtable on pharmaceutical policy. Organized by the Management Faculty at Laval University (André Côté). Local 2307 – Pavillon Palasis Prince, Université Laval. Discussion about biologics and biosimilars..
- April 14 2015 (Ottawa): “The Case for a Universal Pharmacare Program in Canada”. Presentation for the UOttawa Aesculapian Society and The Global Health Advocacy Program. University of Ottawa, Roger-Guindon.
- March 18 2015 (Ottawa) : « Legal considerations about the potential implementation of Universal Pharmacare in Canada”. Presentation for the course CML 1105, Health Systems Law and Policy, Ottawa University (Instructor: Colleen Flood).
- March 17 2015 (Ottawa): “Why Canada needs universal drug coverage”. Presentation for CUPE National Health Care Issues Committee Meeting. CUPE headquarters in Ottawa.
- January 30 2015 (Paris) : « Les stratégies de gestion fantôme dans le capitalisme cognitif : le cas du secteur bio-pharmaceutique ». Séminaire Capitalisme Cognitif. Maison des sciences économiques, Université Paris-I Sorbonne.
- January 29 2015 (Paris) : « Pourquoi les médicaments sont-ils si chers? Les dérives d’un modèle d’affaires ». Présentation for « Gala de la Pilule d’or 2015», organised by *Association Mieux Prescrire*, à l’Espace St-Martin.

- December 15 2014 (Ottawa) : “The Case for a National Pharmacare Program”. Presentation for *Canadian Health Professionals Secretariat*.
- December 9 2014 (Quebec City): « Financement et coherence du système de santé : La nécessité d’un régime public universel d’assurance-médicaments ». Presentation for *Deuxième rendez-vous national sur l’avenir du système public de santé et de services sociaux*, organized by Association québécoise d’établissements de santé et de services sociaux (AQESSS), Confédération des syndicats nationaux (CSN), and Institut du Nouveau Monde (INM). Hotel Le Concorde.
- November 26 2014 (Montreal) : “Roadmap to a Rational Pharmacare Policy”. Presentation for MAPOL Inc’s 5th Annual Private Payer Pulse Education and Training Seminars.
- November 20 2014 (Montreal) : « Les stratégies corporatives de gestion fantôme; Le cas du secteur pharmaceutique ». Présentation for Médicament Objet Social (MÉOS), Université de Montréal.
- November 6 2014 (Montreal): « Économies d’un régime entièrement public ». Presentation for Union des Consommateurs : Journée d’étude Priorité assurance médicaments entièrement publique – Adopter les meilleures pratiques pour l’équité et les finances publiques. Hosted by Quebec’s ex-Minister of Health Jean Rochon (who implemented the current Pharmacare regime in Quebec).
- October 28 2014 (Ottawa): “Roadmap to a Rational Pharmacare Policy in Canada”. Presentation for the 25<sup>th</sup> Anniversary lecture series organized by the Canadian Agency for Drugs and Technology of Health (CADTH).
- October 8 2014 (Quebec City): “Les stratégies corporatives de gestion fantôme; Le cas du secteur pharmaceutique”. Presentation for the course COM 3000: Ethique de la communication publique (Professor : Florence Piron).
- October 1 2014 (Ottawa): “Canadian Drug Prices and Pharma R&D: What do we get for all that money?” Presentation for the Town Hall meeting organized by the Patented Medicines Price Review Board (PMPRB).
- June 24 2014 (Bordeaux, France) : « Les stratégies corporatives de gestion fantôme; Le cas du secteur pharmaceutique ». Presentation for Groupe de Recherche en Économie Théorique et Appliquée (GREThA), Université Montesquieu Bordeaux-IV.
- June 23 2014 (Bordeaux, France): « La recherche médicale au service des firmes ; comprendre les stratégies corporatives de capture scientifique ». Presentation for Institut de Santé Publique, d’Épidémiologie et de Développement (ISPED).
- April 25 2014 (Kansas City, Missouri, USA): “Capital accumulation through institutional corruption; A Veblenian perspective on the ghost-management of the economy”. Celebrating the Life and Works of John Henry. Linda Hall Library, University of Missouri in Kansas City.
- November 21 2013 (Ottawa): Presentation on capitalization of institutional power for Doctoral Seminar at the School of Public Policy and Administration, Carleton University (Instructor: Saul Schwartz).
- November 13 2013 (Toronto): “The Evolution of Quebec's Pharmaceutical Innovation Policy: Some Critical Insights”. Presentation for the Conference *Market Access Summit*, organized by the Strategy Institute. Trump International Hotel and Tower.

- October 9 2013 (Ottawa): “The Emergence of Corporate Science”. Presentation for the graduate course “Introduction to Biomedical Engineering”, Carleton University. (Instructor: Andy Adler).
- April 26 2013 (Quebec City): Expert Roundtable on pharmaceutical policy. Organized by the Management Faculty at Laval University (André Côté). Local 2307 – Pavillon Palasis Prince, Université Laval. Discussion about Quebec Pharmacare, bulk-purchase and health technology assessment in Quebec.
- March 25 2013 (Ottawa): « Bien commun: une approche pragmatique pour les politiques publiques ». Conference *Bien Public et Participation*, School of Political Studies, University of Ottawa.
- March 11 2013 (Ottawa): “The Ghostmanagement of Medical Research”. Presentation for the undergraduate course Science, Culture & Society: Social Studies of Science, Sociology and Anthropology, Carleton University (Instructor: Ariel Fuenzalida).
- February 12 2013 (Montreal): “IP and the Canadian Pharmaceutical Sector; From innovation economy to Corporate Welfare”. Presentation for the IP Week organized by the Center for Intellectual Property Policy, McGill University.
- November 29 2012 (Ottawa): Presentation on capitalization of institutional power for Doctoral Seminar at the School of Public Policy and Administration, Carleton University (Instructor: Saul Schwartz).
- October 25 2012 (Ottawa): “The Emergence of Corporate Science”. Presentation for the graduate course “Introduction to Biomedical Engineering”, Carleton University. (Instructor: Andy Adler).
- October 18 2012 (Montreal) : « Pharma-Québec et un régime public universel d’assurance-médicaments ». Presentation for *Médecins Québécois pour un Régime Public en Santé*. Ste-Justine Hospital.
- September 11 2012 (La Malbaie, Qc): « Le régime québécois de l’assurance-médicaments : Pour une couverture publique universelle ». Presentation for the Canadian Pension and Benefits Institute. 18<sup>th</sup> Quebec Regional Conference, Fairmont Manoir Richelieu.
- August 16 2012 (Ottawa): Participation and Contribution to the Webinar *Pharmaceutical Policy in Canada; Background and Research Potential*. Organized by the CIHR funded Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) program.
- August 12 2012 (Charlottetown, PEI): “Making the Case for a National Drug Plan: Access, Cost and Health Outcomes”. Presentation for the Canadian Society of Hospital Pharmacists, Summer Educational Sessions.
- May 1 2012 (Toronto): “Making the Case for a National Pharmacare Program”. Presentation for the Conference *Pharma Pricing, Reimbursement and Market Access*, organized by Insight. St-Andrew’s Club and Conference Center.
- April 20 2012 (Québec): Atelier sur la chaîne du médicament. Round-table for the MBA Program in Pharmaceutical Management at Université Laval (Organized by Director André Côté).
- March 22 2012 (Ottawa), jointly with Allan Maslove : “Canadian Health Accord Renewal”, Brown-Bag Seminar organized by the SPPA Policy Analysis Concentration, Carleton University.
- March 20 2012 (Hamilton): “Enhancing Canadians’ Prescription Drug Coverage: How the Public and Private Sectors can Work Together to Ensure Affordable Access for Canadians”. Round-Table organized by Center for Health Economics and Policy Analysis, jointly with Canadian Life and Health Insurance Association, McMaster University.

January 2012 (Paris) : « Recherche clinique sous influence : Penser les alternatives ». Présentation for « Gala de la Pilule d'or », organised by *Association Mieux Prescrire*, à l'Espace St-Martin.

November 16 2011 (Gatineau): « Coûts et bénéfices de l'aide financière publique au secteur pharmaceutique canadien ». Presentation for the course “Analyse Coûts-Bénéfices” at Université du Québec en Outaouais. (Instructor : Alexandre Couture Gagnon).

November 10 2011 (Ottawa): “The Ghostmanagement of Medical Research”. Presentation for the undergraduate course “Ethics, Research Methods, and Standards for Biomedical Engineering”, Carleton University. (Instructor: Adrian Chan).

November 9 2011 (Ottawa): “The Emergence of Corporate Science”. Presentation for the Graduate course “Introduction to Biomedical Engineering”, Carleton University. (Instructor: Andy Adler).

November 2-3 2011(Toronto): “Understanding the implications of the Comprehensive Economic and Trade Agreement (CETA) on innovative and generic companies”. Debate with Len Edwards, ex-Deputy Minister of Foreign Affairs, organized by Eye for Pharma for the third annual *Market Access Canada* Conference. Hotel Marriott.

October 21 2011 (Toronto): “The Evolving Business Model of the Global Pharmaceutical Industry”. Conference *New and Emerging Issues on Pharmaceutical Access*, organized jointly by the Initiative for Drug Equity and Access and the Leslie Dan Faculty of Pharmacy at University of Toronto.

October 17 2011 (Ottawa): Presentation on the political context for reforming public drug coverage in Canada, for the Course “Federalism and Public Policy in Canada” at Ottawa University (Instructor: Gord Di Giacomo).

September 29- October 1 2011 (Dubrovnik, Croatia): Presentation for European Regulatory agencies about the dominant business model in the pharmaceutical sector. Conference *Les informations sur les médicaments*, organized by HALMED, the Croatian regulatory agency for prescription drugs.

April 29 2011 (Guananoque): “The Ghostmanagement of Medical Research; The Emergence of Corporate Science”. Carleton Spring Conference. Glen House Resort.

December 10 2010 (Winnipeg): “The Economic Case for Universal Pharmacare”. Community Health Sciences Colloquium Series, University of Manitoba.

December 10 2010 (Winnipeg): “Dominant Business Model in the Pharmaceutical Sector: Medical Knowledge Under the Influence”. Faculty of Medicine, University of Manitoba.

November 30 2010 (Toronto): “The Economic Case for Universal Pharmacare”. Canadian Association of Business Economics. Conference at Industry Canada.

November 26 2010 (Ottawa): “Promotion and Corruption as the dominant Business Model in the Pharmaceutical Sector”. Carleton University Health Policy Workshop.

November 17 2010 (Cambridge, Boston): “Rising Profits and Declining Innovation in the Pharmaceutical Sector: When Promotion and Corruption Become a Business Model”. Presentation for the Edmond J. Safra Center for Ethics at Harvard University.

November 3 2010 (Ottawa): “The Dominant Business Model in the Pharmaceutical Sector; Medical Knowledge under the Influence.” Faculty of Medicine, Ottawa University (Invitation by the Health Policy Interest Group).

- October 4 2010 (Paris): Séminaire ENTSA at ParisTech: "The Dominant Business Model in the Global Pharmaceutical Sector; Corruption and Promotion, but no Innovation".
- October 1 2010 (Paris): Séminaire Capitalisme Cognitif at Maison des Sciences Économiques (Paris-I Sorbonne): "Intellectual Property as a pitfall for Industrial Modernity; The case of pharmaceutical patents".
- September 28 2010 (Paris): Séminaire Hétérodoxies at Maison des Sciences Économiques (Paris-I Sorbonne): "The Veblenian approach to the nature of capital; Rethinking accumulation in the knowledge-based economy".
- "Universal Pharmacare for Canada; Costs and Benefits of Publicly Funded Universal Drug Coverage." Conference for the *Pharmaceutical Policy Research Collaboration*. Toronto, May 2010.
- "Understanding the Business Model of Big Pharma; Medical Knowledge under the Influence." Presentation for *Epidemiology, Biostatistics and Occupational Health Seminar Series*. McGill University, May 2010.
- "Patents, Innovation and Profits; Patients Shortchanged by Big Pharma." Presentation for World TB Day Panel Discussion, Organized by McGill Global AIDS Coalition. McGill University, April 2010.
- "Les politiques canadiennes en faveur de l'innovation pharmaceutique: Le jeu en vaut-il la chandelle?" Conference-debate about policies of Patented Medicine Price Review Board. Centre for Law, Technology and Society, Ottawa University, March 2010.
- "Pharmacare for Canada: When social policy conflicts with innovation policy". School of Public Policy and Administration, Carleton University, March 2010.
- "Quand la corruption de la science médicale accroît les profits." Faculty of Law, Sherbrooke University, February 2010.
- "Les défis éthiques du marketing pharmaceutique", Workshop for the course Introduction à la Médecine Clinique, Faculty of Medicine, UdeM, March 2010 (also in 2009 and 2008).
- "The Dominant Business-Model in the Pharmaceutical Sector; Profits Based on Control over Medical Knowledge". Lecture in front of 150 family physicians for the *McGill Continuing Medical Education*, November 2009. The video presentation of the lecture was shown at the 2010 Canadian Conference on Medical Education in St. John's, Newfoundland.
- "In the Name of Competitiveness; Exploring the Cost of Canadian Technological Leadership in the Pharmaceutical Sector". Lecture for the *Pharmaceutical Policy Research Collaboration*. Ottawa, November 2009.
- "H1N1 : Peut-on faire confiance à la science médicale en temps de crise?" Presentation for Café des Sciences : *Grippe, Pandémie... Les vaccins nous protègent-ils?* Collège Montmorency, Laval, November 2009.
- "Darwinisme social hier et aujourd'hui; quand la théorie de l'évolution est mise au service des élites". *Holocaust Education Series*. Montreal Holocaust Memorial Centre, October 2009.
- "Marchandisation des savoirs: Des tendances injustifiables". Grande Conférence du Forum Social Québécois. Montreal, October 2009.
- "Le modèle d'affaires pharmaceutique: Des profits fondés sur le contrôle du savoir médical", Conference for *Collège des médecins du Québec*, Montreal, June 2009.
- "La crise: mécanismes financiers et conséquences citoyennes", Conference for ATTAC-Québec/Centre Justice et Foi, Montreal, May 2009.



- “Promotion, recherche et profits dans le secteur pharmaceutique”, Conference for Sanofi-Aventis/Université de Sherbrooke, Laval, March 2009.
- “Pourquoi la théorie économique échoue le test de la réalité industrielle; le cas des pharmaceutiques”, Presentation for an Éco-lunch in Economics, UQAM, April 2008.
- “L’industrie pharmaceutique et l’intérêt général: Dérives éthiques et économiques”, Presentation for Centre de Recherche sur l’Éthique à l’UdeM, December 2007.
- “Capital, Knowledge and Power in the Global Pharmaceutical Business”, Seminar for *Center for Intellectual Property Policy*, McGill University, May 2007.
- “Les droits de propriété intellectuelle sont-ils un écueil à la modernité industrielle”, Workshop on Property for the Journal *Société*, UQAM, May 2007.
- “Capitalisation de la connaissance et du pouvoir; l’approche véblénienne du capital”, Summer University in History of Economic Thought, Université de Grenoble 2, 2005.
- "Measuring exchange-value: Evaluation of Ricardian and Aristotelician Traditions", Workshop *Labour Theory of Value; A Reappraisal*, York University, March 2002.

### 3. RESEARCH GRANTS AND RESEARCH CONTRACTS

|  |           |
|--|-----------|
| Co-investigator for a Jean-Monnet Networks Grant to Build capacity on the study Of European Health Policy. With Katherine Fierlbeck and Tom Jefferson, Marc-Andre Gagnon will focus on Regulation and Transparency in Pharmaceutical Policy, and he will organize a Summer School at Carleton University on this topic In May-June 2020 (\$42,000 for the Summer School).  | 2017-2021 |
| Lead investigator for a CIHR Catalyst Grant in Ethics (\$84,000 for 2 years)<br>Research Topic: <i>Assessing the Ethics of the Dominant Business Model in the Canadian Pharmaceutical Sector; Tackling Institutional Corruption through Regulatory Reforms</i> . Co-investigator: Jillian Clare Kohler (University of Toronto). Collaborators: Sergio Sismondo, Joel Lexchin, Paul Grootendorst, Barbara Mintzes, Lisa Cosgrove, Richard Gold, Marc Hasbani. | 2012-2017 |
| Lead investigator for a Health Canada research contract to write a report on Types of funding for a national drug plan. (\$12,000 in research funds). Deliverables on June 30 2016.  | 2015-2016 |
| Co-investigator. <i>Les nouvelles stratégies promotionnelles des fabricants de médicaments; fidélisation, accompagnement et compassion</i> . Research project with Marie-Claude Prémont (École Nationale d'Administration Publique, Montréal). Funding of (\$10,000) by Ordre des Pharmaciens du Québec for the production of a report and for organizing a one-day conference with other professional orders in the Quebec health sector.                   | 2013-2014 |
| Lead investigator. <i>Updating the case for Universal Pharmacare</i> . (\$12,000)<br>Analysis of the impact of a bulk purchasing agency for prescription drugs, models for funding pharmacare, and recent evolution of pharmaceutical policies. Funding provided by the <i>Canadian Federation of Nurses Unions</i> .  | 2012-2014 |
| Co-investigator. <i>Understanding health benefits negotiations in private sector settings</i> . Research project with Sean O'Brady (MAPA student) and Alan Cassels (University of Victoria). Funding of (\$1,000) obtained from the Canadian Health Coalition for the transcription of interviews.   | 2013-2014 |
| Research Fellow for the <i>Pharmaceutical Policy Research Collaboration</i> , Co-researcher on Emerging team grant from CIHR (\$1.5 M for 5 years). Research on pharmaceutical innovation and consulting with policy-makers.   | 2009-2014 |
| <i>Edmond J. Safra Foundation Center for Ethics (Harvard University)</i> . External Fellowship for the "Lab Project on Institutional Corruption". Directed by Lawrence Lessig. (Stipend: \$15,000; +\$3000 in research funds). Research Topic: Political Economy of Pharmaceutical Corruption.   | 2010-2012 |
| <i>Best Brains Exchange Travel Award</i> . Award for participating to Ontario Best Brain Exchange on provincial healthcare funding (\$1000 + Travel Expenses).   | July 2011 |
| Leader on a Health Canada research contract for a report describing the cost of tax incentives in pharmaceutical R&D as compared to the value of economic  | 2010-2011 |

spinoffs (\$9990, including \$3125 in research funds). Jointly with Richard Gold. Deliverables submitted on March 31 2011.

|  |           |
|--|-----------|
| Co-leader for a Health Canada contract (\$50,000) for a report on the impact of intellectual property policies on pharmaceutical innovation. The project is led by Benedicte Callan from University of Texas in Austin. Collaborators include Richard Gold, Jean-Frederic Morin, Barbara Slater, Mélanie Bourassa-Forcier and Tania Bubela. Deliverables submitted June 30 2011. | 2010-2011 |
| Consulting for <i>Quebec's National Assembly</i> . (\$8,000)<br>Developing guidelines for a coherent pharmaceutical policy in Quebec.  | 2010      |
| Post-doctoral Fellowship <i>Fonds Québécois de Recherche sur la Société et la culture</i> (\$74,000 for 28 months).<br>Research topic: Determinants of pharmaceutical investment.  | 2009-2010 |
| Lead, Research project funded by the <i>Canadian Health Coalition</i> (\$12,000)<br>Comparative analysis of national public drug programs, making the economic Case for universal pharmacare in Canada.  | 2009-2010 |
| <i>Fonds pour la formation de chercheurs et l'aide à la recherche</i> Doctoral Fellowship \$20,000\$ per year for three years of doctoral study.   | 1999-2002 |

#### **4. OTHER PROFESSIONAL ACTIVITIES**

##### **Peer-Reviews:**

From May 2011 to Present: Regular Peer-Reviewer for the *Canadian Medical Association Journal*.

From July 2010 to Present: Regular peer-reviewer for the journal *Healthcare Policy*.

July 2016: Peer-review of one article about Financialization for *Interventions Économiques*.

January 2016: Peer-review for a paper in *Accountability in Research*.

March 2015: Peer-Review for a paper for the *British Medical Journal*.

February 2015: Peer-Review for a paper for *PLoS Medicine*.

September 2014: Peer-review of an article about access to cancer drugs for *Health Policy*.

May 2014: Peer-Review of an article on pharmaceutical marketing for *PLOS Medicine*.

December 4-5 2013: Peer-Review for CIHR research grants submissions.

November 2012: Peer-Review for CIHR research grants submissions.

August 2012: Peer review of a chapter on the politics of intellectual property for a book on intellectual property (following a conference at University of Ottawa).

June 2012: Peer Review of an article on Product Listing Agreement for the *Alberta Law Review*.

May 2012: Peer-Review of an article on the dominant business model in the pharmaceutical sector for the journal *Industrial and Corporate Change*.

April 2012: Peer-Review of an article on Schumpeter for *Interventions Économiques*.

September 2011: Peer-Review for an article on evolution in economics for *Économie et Société*.

February 2011: Peer Review of Fellowship Award for the Pharmaceutical Policy Research Collaboration.

February 2011: Peer-Review of Rising Star Awards for IHSPR.

January 2011: Peer-review of a manuscript on Pharmaceutical Ethics for Lux Editeurs

October 2010: Peer-review of a report on the value of pharmaceutical innovation for Canadian Agency for Drugs and Technologies in Health.

October 2010: Peer-review of a report on the management of pharmaceutical expenditures for Canadian Health Services Research Foundation.

August 2010: Peer-Review for 3 CIHR submissions (Meeting, Planning and Diffusion Committee).

August 2010: Peer-review of one article about John R. Commons for *Interventions Économiques*.

**Service to the Profession:**

|  |           |
|--|-----------|
| Organization of the International Symposium: Combating Corruption in Health Care and Pharmaceuticals. Organized with the WHO Collaborating Centre for Governance, Accountability and Transparency in the Pharmaceutical Sector. Munk School of Global Affairs, University of Toronto.          | Nov 2016  |
| Organization of the Symposium: “How to ensure appropriate and safe use of Medications in Canada?” Organized by the Rational Therapeutics and Medication Research Group during Carleton University’s Faculty of Public Affairs Research Month. Carleton University, Ottawa.                     | Feb 2016  |
| Organization of an international conference: <i>Rethinking Drug Coverage in Canada; Is it time for Universal Pharmacare?</i> Organized by the <i>School of Public Policy And Administration at Carleton University</i> , and by the <i>Canadian Health Coalition</i> . Hotel National, Ottawa. | May 2013  |
| Organization of the sub-plenary panel <i>Drug Insurance in Quebec: Model or Foil</i> , for the Conference of Canadian Association for Health Services and Policy Research (CAHSPR) 2012.   | May 2012  |
| Organization of workshops on drug promotion for Medecine students University of Montreal   | 2008-2012 |
| Organization of training workshops for NGOs on globalization, the financial crisis and the commodification of knowledge (Around 20 workshops since 2004)   | 2002-2009 |
| Organization of a new program in Ecosanté (Ecosystemic approach to Health) Faculté de l’Éducation Permanente, Université de Montréal   | 2007-2008 |

## **F. ACADEMIC RESPONSIBILITIES**

### ***TEACHING AND ACADEMIC EXPERIENCE***

#### **Visiting Professor**

July 2016 - July 2017 : University of Ottawa: Visiting Professor with the Centre on Health Law, Policy and Ethics.

Summer 2014: Université Montesquieu Bordeaux-IV (France): Visiting Professor with the Groupe de Recherche en Économie Théorique et Appliquée. PhD Economics Course offered: *Capital, science et pouvoir : les dynamiques d'accumulation dans l'économie du savoir*.

#### **Graduate courses taught**

##### At Carleton University:

PADM 5115: Intro to State and Society (Winter 2011, Fall 2011, Winter 2012, Winter 2013, Winter 2014 (twice), Winter 2015 (twice), Fall 2015, Winter 2016)

PADM 5228: Social Policy (Summer 2011, Winter 2012, Fall 2012, Fall 2013, Fall 2015)

PADM 5672: Policy Seminar on Pharmaceutical Policy (Summer 2012, 2013, 2015)

##### Elsewhere:

CMPL 605: Regulation, Technology and Society (Winter 2010, Faculty of Law, McGill University)

POL 8010: Théorie du politique (Fall 2007, Political Science, Université du Québec à Montréal)

#### **Undergraduate courses taught**

##### At Carleton University:

PADM 1000: Introduction to public affairs and policy management: History of economic thought (Winter 2013, Winter 2014, Winter 2015, Winter 2016)

##### Elsewhere:

ECN 1600: Histoire de la pensée économique (Offered 10 times from 2002 to 2009). Course in the Economics Department, University of Montreal.

ECO 3062: Histoire de la pensée économique jusqu'au XIXe siècle (offered 3 times from 2008 to 2009). Courses in the Economics Department, Université du Québec à Montréal.

ECO 4062 : Histoire de la pensée économique au XXe siècle (Winter 2009). Course in the Economics Department, Université du Québec à Montréal.

SOC 4301 : Sociétés Actuelles et mondialisation (Offered 7 times from 2002 to 2009). Courses in the Sociology Department, Université du Québec à Montréal.

SOC 5125 : Théories sociologiques contemporaines (Fall 2004). Course in the Sociology Department, Université du Québec à Montréal.

## ***SUPERVISION AND EXAMINATION OF DISSERTATIONS***

### **Supervisions completed**

#### PhD Level:

September 2014-July 2017: Member of the supervisory committee for the PhD dissertation of Adrienne Shnier (Graduate Program in Health, York University): *Medical Education and Financial Conflict of Interest Relationships with the Pharmaceutical Industry in Canada: An Analysis of Four Areas of Medical education.*

Spring 2014-December 2017: Member of the supervisory committee for the PhD dissertation of Mathieu Charbonneau (Sociology, Carleton University): *Insurance Risks as Fictitious Commodities: The Institutional Constitution of Insurance Markets.*

Fall 2013-Fall 2014: External Examination of PhD Dissertation by Ghislaine Mathieu, (Bioethics, Université de Montréal): *Approbation, mise en marché et surveillance après mise en marché des dispositifs médicaux à risque élevé : Examen des enjeux socio-éthiques*

March 2014: Member of the supervisory committee and Internal examiner of PhD Dissertation by Bruce Currie-Adler on R4D Governance.

March 2012: External Examination of PhD Dissertation by Caroline Cambourieu (Health Administration, Université de Montréal) about Québec's Pharmacare regime.

#### MA Level:

2015-2016: MA Dissertation by Russel Burgess: *Competition or Liberation? Implications of Labour Automation in the Context of Cognitive Capitalism.*

2015-2016: Research essay by Marion Haas on paediatric drug testing.

Winter 2015: Directed Study by Karena Volesky on adaptive licensing of pharmaceuticals and pharmacovigilance.

Fall 2014: Directed study by Kevin Nugent on recent literature on Income inequality.

2012-2014: MA thesis by Jason Dolny: *Gramsci and Ghostwriting: Revisiting Medical Journal Conflict of Interest Policies in an Age of Neoliberal Science.*

2013-2014: MA Research essay by Kathleen Dyson (Institute of Political Economy): *Canada's new medical marijuana regulations: birthing an industry at the expense of patients?*

2012-2014: MA candidate Shpresa Loshaj for the CIHR Training Program in Bridging Scientific Domains for Drug Safety and Effectiveness (DSect Program). Loshaj wrote her SPPA Directed Study in the Fall 2013 based on the material learned in the program.

Fall 2013: Directed study by MA candidate Darrell Harvey on defining the central features of the discourse about the knowledge-based economy.

May 2013-August 2013: MA Candidate Jennifer Barr's directed study on the alcohol lobby in Canada.

September 2012-December 2012: MA candidate Tamreen Arif's directed study on exploring the pathways to inequality.

June 2012-August 2012: MA candidate Sean O'Brady's Directed Study on the negotiation of private drug plans in a unionized context

June 2012-August 2012: MA candidate Philip Oakley's Directed Study on advertising and tax incentives

July 2011: External examination of the MA Dissertation by Matthieu Charbonneau (Sociology, UQAM) about the sociology of risk and insurance in the works of Ulrich Beck.

October 2010: External evaluation of the MA Dissertation of Caroline Joly (Sociology, UQAM) about the concept of "Technoscience" in the works of Michel Freitag.

B.A. Level:

2015-2016: Honors Research Essay by Sean Mallard on the development of the Craft beer industry in Quebec and Ontario.

January 2012-March 2012: Honors Research Essay by Diana Volesky on the clinical and pharmacoeconomic assessment on new anti-cancer drugs

**Supervisions in progress (Was on Sabbatical from July 2016 to July 2017)**

PhD Level:

None

MA Level:

None

B.A. Level:

None

## G. ADMINISTRATIVE RESPONSIBILITIES AT CARLETON UNIVERSITY

|  |                              |
|--|------------------------------|
| Member of Admission Committee, PhD in Public Administration<br>School of Public Policy and Administration  | January 2016-June 2016       |
| Member of the jury for the Public Commentary Award, Faculty of Public<br>Affairs, Carleton University.   | April 2016                   |
| Representative of SPPA<br>Arthur Kroeger College   | September 2015-June 2016     |
| Leader of the Policy Analysis concentration<br>School of Public Policy and Administration (SPPA) at Carleton University                                | September 2011-June 2016     |
| Member of Admission Committee, Masters of Public Administration<br>SPPA at Carleton University   | November 2014-January 2016   |
| Member of Carleton University's bio-hazards committee  | December 2011-June 2016      |
| Member of Hiring Committee for a SPPA professor position<br>at Carleton University   | August 2015-January 2016     |
| Representative of SPPA<br>Board of Faculty of Public Affairs at Carleton University  | 2011-2015                    |
| Member of Hiring Committee for a SPPA professor position<br>at Carleton University   | August 2014-January 2015     |
| Member of Hiring Committee for a SPPA professor position<br>at Carleton University   | February 2014-May 2014       |
| Member of Hiring Committee for a tenure-track position<br>SPPA at Carleton University  | September 2012-May 2013      |
| Member of Admission Committee, Diploma in Program Evaluation<br>SPPA at Carleton University  | September 2012-November 2014 |
| Preparation of the French Exam for SPPA PhD students<br>at Carleton University   | April 2012-June 2016         |
| Member of Hiring Committee for Visiting Professors<br>Institute of Political Economy, Carleton University  | January 2013                 |
| Prepared reading list and questions for PhD Comprehensive Exam<br>in social policy, in collaboration with Jennifer Stewart. Evaluation<br>of the exam. | April 2012-September 2012    |
| Participated in assembling cross-disciplinary MA and diploma programs in<br>Health Science, Technology and Policy (under the auspices of Kim Matheson, | 2011-2012                    |



V-P research at Carleton University).

Prepared reading list and questions for PhD Comprehensive Exam in Political Economy in collaboration with Phil Ryan. Evaluation of the exam.

April 2011-September 2011

Organized with Jennifer Stewart a meeting for people from IHSPR to discuss the application process for CIHR research grants with social scientists working on health issues.

January 18, 2011

Organized with Jennifer Stewart a meeting with Colleen Flood from IHSPR to discuss the applications process for CIHR research grants with social scientists working on health issues.

December 14, 2010

## H. OTHER

### ***KNOWLEDGE TRANSLATION ACTIVITIES AND PUBLIC POLICY MEETINGS***

- January 30 2017 (Ottawa): Presentation on Canadian Pharmacare for the National Lobby Conference, organized by the Canadian Health Coalition.
- November 15 2016 (Montreal): Presentation on Canadian Drug Prices as columnist for the Radio show “Les Éclaireurs” (Radio-Canada).
- June 29 2016 (Ottawa): Presentation for Health Canada staff about “Financing the Public Provision of Prescription Drugs in Canada; Comparison and Assessment of Financing Options”. Tunney’s Pasture, Ottawa.
- June 1 2016 (Toronto): Two presentations for the Oncology Roundtable on National Pharmacare (on how should national Pharmacare look and cost, and on international comparisons). Organized by the Canadian Cancer Survivors Network. Sunnybrooke Estates, Toronto.
- May 31 2016 (Ottawa): Breakfast Presentation at Canadian Parliament for Members of Parliament: “Backgrounder on Drug Coverage in Canada; Filling the Prescription”. Presentation organized by the Canadian Federation of Nurses Unions.
- May 11 2016 (Toronto): Roundtable “Formulary 2020” discussing required evidence to establish a national drug formulary. The roundtable was organized in the context of the CAHSPR Conference 2016.
- April 18 2016 (Ottawa): Presentation on “Development of a National Pharmacare Program”. Testimony for the Standing Committee on Health. House of Commons, Government of Canada: <https://openparliament.ca/committees/health/42-1/7/>
- March 10 2016 (Quebec City): Presentation on Bill 81 about the implementation of a tendering process for generics in Quebec. Testimony for Commission de la santé et des services sociaux, Quebec National Assembly.
- January 22 2016 (Ottawa): Best Brains Exchange organized by the Canadian Institutes for Health Research. Topic: *Quality of drugs manufactured in emerging economies: Are cost-containment strategies heightening the likelihood of substandard drugs in Canada?* CIHR Office.
- December 15 2015 (Ottawa): United Towards a Health Accord. Roundtable organized by the Canadian Federation of Nurses Unions. Westin Hotel.
- December 7 2015 (Montreal): Meeting with Abbvie Canada’s directing board on the challenges of Canada’s pharmaceutical industry.

- November 30 2015 (Trois-Rivières, Quebec): “Le régime hybride actuel est-il viable? Quelles sont les alternatives?” Journée de réflexion de la Fédération des Travailleurs du Québec *L’Assurance-médicaments à la croisée des chemins*. Delta Trois-Rivières.
- October 8 2015 (Toronto): National Pharmacare Policy Roundtable (with stakeholders including drug companies, insurance companies, medical associations and patient advocacy groups). Organized by Janssen. MaRS Centre.
- October 6 2015 (Ottawa): 2 presentations, one on high cost impact drugs, the other on the design of a national drug plan. Researchers Forum for the Patented Medicines Price Review Board. PMPRB Office.
- April 27 2015 (Ottawa): Policy brief with Murray Rankin, Health critic for the NDP, about federal costs for implementing universal pharmacare.
- March 26 2015 (Ottawa): Roundtable discussion about “Analysis and Options for a Tax-Assisted Savings for Meeting Out of Pocket Health Care Costs”, organized by the Federal Health Minister’s *Healthcare Innovation Advisory Panel*. Fairmont Château Laurier.
- December 8 2014 (Ottawa): Policy Brief with Liberal MP Hedy Fry in Parliament, West Block. Presentation of the report “Roadmap to a Rational Pharmacare Policy in Canada.”
- November 26 2014 (Montreal): Meeting with Institut NeoMed’s President Max Fehlmann and Chief Scientific Officer Philippe Walker to discuss alternative business models in the Canadian pharmaceutical sector.
- November 23 2014 (Ottawa): Presentation on universal pharmacare for the Canadian Federation of Medical Students. Held at the Canadian Medical Association in preparation for their lobby day in Parliament.
- September 23 2014 (Ottawa): Presentation for the Trade and Investment Research Project (TIRP) organized by the Canadian Centre for Policy Alternatives. Presentation on the impact of the Comprehensive Economic and Trade Agreement on the costs of prescription drugs.
- September 18 2014 (Ottawa): Policy Brief with the NDP (10 MPs), in Parliament, East Block. Presentation of the report “Roadmap to a Rational Pharmacare Policy in Canada.”
- August 27 2014 (Charlottetown, PEI): Breakfast Presentation at the Council of the Federation, Delta Hotel. Presentation of the report “Roadmap to a Rational Pharmacare Policy in Canada.” **The presentation was attended, among others, by the Premiers of Ontario, Prince-Edward Island, Nova Scotia, Manitoba, and Yukon and the Chiefs of Staff of some of the other provinces.**
- August 21 2014 (Ottawa): Researcher forum organized by the National Prescription Drug Utilization Information System (NPDUIS).
- February 13 2014 (Ottawa): Appearance to the House of Commons’ Standing International Trade Committee. Contribution to “Canadian-European Union Comprehensive Economic and Trade Agreement”: <http://openparliament.ca/committees/international-trade/41-2/18/dr-marc-andre-gagnon-1/>
- February 3 2014 (Laval). « Argumentaire économique pour un régime universel d’assurance-médicaments; Coûts et bénéfices d’une couverture publique pour tous ». Présentation for the reflection day *La privatisation du système de santé québécois - État des lieux et planification stratégique* organized by Syndicat Canadien de la Fonction Publique (SCFP).

- November 27 2013 (Montreal). « Nouvelles stratégies commerciales des fabricants de médicaments: tendances internationales et québécoises ». Joint presentation with Marie-Claude Prémont for a reflection day with healthcare professionals' representatives, organized by Ordre des pharmaciens du Québec.
- October 25 2013 (St-Hubert). "La nécessité de contenir les coûts au public et au privé dans le régime québécois d'assurance-médicaments". Presentation for 250 retired teachers from Association des retraités de l'enseignement du Québec (AREQ) de la Montérégie.
- September 12 2013 (Ottawa). "Current Trends and Issues in the Canadian Pharmaceutical Sector." Presentation to the Directing Board of the Patented Medicines Price Review Board. PMPRB Building.
- July 24 2013 (Niagara-on-the-Lake): "Roadmap to a Rational Drug Policy; Time for Canadians to enter the 21<sup>st</sup> Century." Breakfast Presentation to Provincial Premiers' staff during Council of the Federation. Pillars and Post Hotel.
- June 18 2013 (Laval): "Le régime québécois de l'assurance-médicaments : La nécessité d'un régime public universel." Presentation for 300 union delegates from the Fédération des Travailleurs du Québec SQEES-298 (Syndicat québécois des employés et employées de service): <http://www.youtube.com/watch?v=j7L3wgEj9hc>
- April 27 2013 (Toronto): "Access, Costs and Equity: The Case for Universal Pharmacare". Students for Medicare, 5th Annual Conference: "Expanding the Canada Health Act: Pharmacare and Beyond". United Steelworkers' Hall.
- April 9 2013 (Montreal): « *Le régime québécois de l'assurance-médicaments : la nécessité d'un régime public universel* ». Presentation for Séminaire FTQ Retraites et Assurances, 300 union delegates from the Fédération des Travailleurs et Travailleuses du Québec.
- March 19 2013 (Ottawa): Appearance to the House of Commons' Standing Committee on Health. Contribution to "Study: Technological Innovation".
- January 9 2013 (Quebec City): Expert briefing with Luc Castonguay, Assistant Deputy Minister for the Direction générale de la planification, de la performance et de la qualité (planning, performance and quality assurance branch) in the Quebec ministère de la Santé et des Services sociaux (MSSS).
- December 4 2012 (Ottawa): Meeting with NDP leaders (Thomas Mulcair, Libby Davies) and issue coordinators to discuss pharmaceutical policies in Canada. Parliament, Central Building.
- November 22 2012 (Ottawa): "Drug Regulation in the Age of Corporate Science". All Staff meeting at Health Canada, Biologic and Geneic Therapies Directorate. Tunney's Pasture.
- November 6 2012 (Montreal): Expert briefing with Fédération des Travailleurs du Québec on drug coverage in Quebec. Comité Retraite et Assurances FTQ.
- October 23 2012 (Ottawa): Expert briefing with NDP researchers and issue coordinators on the Comprehensive Economic and Trade Agreement between Canada and Europe.
- June 12 2012 (Ottawa): Appearance to the House of Commons' Standing Committee on Industry, Science and Technology. Contribution to "Study: Intellectual Property Regime in Canada".
- March 5 2012 (Ottawa): "CETA and Health Care in Canada: implications for Health Services and the cost of medicines". Roundtable organized by MP Anne Minh-Thu Quach and MP Brian Masse for Members of Parliament and Senators only.

February 27 2012 (Montreal): “Les défis éthiques du marketing pharmaceutique”, Workshop for the course Introduction à la Médecine Clinique, Faculty of Medicine, University of Montreal.

December 1 2011 (Ottawa): Meeting with NDP members (Nycole Turmel, Libby Davies, Guy Caron, François Lapointe and Djaouida Sellah) to discuss scenarios for universal Pharmacare in Canada.

November 30 2011 (Ottawa): Presentation on Universal Pharmacare for a televised conference organized by the Canadian Health Coalition: “Save the Future of Medicare; A Call to Care”. Château Laurier.

September 3 2011 (St-Alphonse de Rodrigue, Quebec): Meeting with Quebec Solidaire to discuss the Pharma-Quebec Initiative.

July 13 2011 (Toronto): Best Brains Exchange about the provincial funding of healthcare, for public employees at the Ministry of Health and Long Term Care (including the Deputy Minister and 3 Assistant Deputy Ministers).

May 26 2011 (St-John’s, Newfoundland): Breakfast conference for the members of Parliament. Organized by Newfoundland and Labrador Nurses’ Union.

April 18 2011 (Ottawa): Meeting with Directors from Pfizer Canada: Farzad Ali (Director, Health Economics and Outcomes Research) and Frédéric Lavoie (Director, Patient Access).

April 5 2011 (Ottawa): Meeting with Senator Kevin Ogilvie about the dominant business model in the pharmaceutical sector.

March 31 2011(Ottawa): “Opportunity Cost: An estimate of public financial subsidies to the Canadian pharmaceutical sector”. Presentation for the staff at Health Canada (Department of pharmaceuticals).

March 7 2011 (Montreal): Participation to a debate over the impact of pharmaceutical marketing for the University of Montreal Medicine Faculty. Organized by Comité de Lutte Anti-Marketing Pharmaceutique.

March 11 2011 (Ottawa): “Rising profits and Declining Innovation in the Pharmaceutical Sector: When promotion and corruption become a business model”. Presentation for the staff at *Canadian Agency for Drugs and Technology of Health (CADTH)*.

March 2 2011 (Ottawa): Meeting with Ujjal Dosanjh (Health Critic for the Official Opposition) and Marc Garneau (Industry Critic for the Official Opposition) about the impact of the Canada-Europe Trade Agreement on the price of patented drugs.

February 15 2011 (Ottawa): Meeting with the Minister of International Trade, the Honorable Peter van Loan about the impact of the Canada-Europe Trade Agreement on the price of patented drugs.

February 10 2011: Letter submitted to the Expert Panel of the Review of Federal Support to Research and Development about the costs of innovation policies in the pharmaceutical sector.

January 19 2011 (Ottawa): Participation to the Technical Discussions on Regulatory Modernization of Pharmaceutical Policy at Health Canada.

January 18 2011 (Ottawa): Meeting with Patented Medicines Price Review Board (PMPRB) about the possibility to modify the way we cap patented drug prices in Canada.

January 18 2011 (Ottawa): Meeting with Conservative MP Terence Young about Regulatory Modernization on pharmaceutical policy at Health Canada.

December 16 2010 (Toronto): Meeting with 3 Ontario ADMs about Universal Pharmacare and innovation policies in the pharmaceutical sector.  
 Participants:  
 -Ernie Bartucci (ADM, Ministry of Intergovernmental Affairs)  
 -Tony Rockingham (ADM, Ministry of Research and Innovation)  
 -Diane MacArthur (ADM, Executive Officer of Ontario Public Drug Program)

December 16 2010 (Toronto): Meeting with Canadian Association of Retired People (CARP) about universal pharmacare.

December 15 2010 (Ottawa): Meeting with Daniel Charron from the Canadian Generic Pharmaceutical Association (CGPA).

November 4 2010 (Ottawa): Meeting with Industry Canada about industrial policy in the Canadian pharmaceutical sector. Participants:  
 -Annette Ryan, Chief Economist and Director General, Economic Research and Policy Analysis Branch  
 -Leah Clark, Director General, Life Science Industries Branch  
 -Marc Duhamel, Director, Market Structure & Framework Policy Analysis  
 -Tereasa Chudy, Manager, Life Science Industries Branch  
 -Adam Slade, Economist, Life Science Industries Branch

October 21 2010 (Montreal): « Argumentaire économique pour un régime public universel d'assurance-médicaments ». Conférence dans le cadre de la journée d'étude de l'Union des Consommateurs sur le coût des médicaments.

October 21 2010 (Montreal): « Le Ghostwriting: Comprendre l'influence des firmes sur la recherche médicale ». Conférence dans le cadre de la journée d'étude de l'Union des Consommateurs sur le coût des médicaments.

October 21 2010 (Montreal) : « Le modèle Kiwi : Comprendre la politique néo-zélandaise d'achat de médicaments prescrits ». Conférence dans le cadre de la journée d'étude de l'Union des Consommateurs sur le coût des médicaments.

October 15 2010: Letter submitted to the INDU Committee Parliament hearings about Bill C-393 for better access to essential medicines.

October 6-8 2010 (Amsterdam): *Selling Sickness* Conference, organized by Healthy Skepticism.

October 4 (Paris): Meeting with Bureau of François Autain, French Senator, about pharmaceutical policy in France.

September 23 2010 (Ottawa): Meeting with Bloc Québécois (Luc Malo, Pierre Paquette and staff) about the implementation of national pharmacare in Canada and Quebec.

September 13 2010 (Ottawa): Press Conference at Parliament about the release of the report *Economic Case for Universal Pharmacare*.

August 27 2010 (Ottawa): Meeting in Ottawa with Federal Liberals (Sandra Schwartz, Policy advisor) about the implementation of national Pharmacare in Canada.

August 25 2010 (Toronto): Meeting with Bureau of Ontario Premier (Dan Corbin) about the implementation of national pharmacare in Canada.

August 10 2010 (Ottawa): Meeting with NDP (Jack Layton, Meghan Leslie and staff) about the implementation of national pharmacare in Canada.

March 2010 (Montreal): “Les défis éthiques du marketing pharmaceutique”, Workshop for the course Introduction à la Médecine Clinique, Faculty of Medicine, University of Montreal.

### **MAJOR RADIO AND TV INTERVIEWS**

« Pensioenfondsen blokkeren prijsverlaging levensreddend medicijn ». Pharmaceutical expert for Zembla episode (Netherlands) on the financialization of the pharmaceutical sector (In Dutch), March 2016: <http://zembla.vara.nl/seizoenen/2016/afleveringen/09-03-2016/pensioenfondsen-blokkeren-prijsverlaging-levensreddend-medicijn>

« L'industrie pharmaceutique sous l'œil du microscope ». Interview for Couleurs Locales, 1 hour TV show, at UNIS. February 2016: <http://unis.ca/couleurs-locales?e=0x84pqt3i8ell>

« Prix des médicaments au Québec; une pilule difficile à avaler ». Entrevue pour Hinnovic, 2014: <http://www.hinnovic.org/le-prix-des-medicaments-au-quebec/>

« Coûts cachés chargés par les pharmaciens ». Interview for the TV Show *JE* on TVA. November 2013: <http://tva.canoe.ca/emissions/je/reportages/202211.html>

« Une assurance-médicaments qui peut coûter très cher ». Interview for the TV show *La Fracture* on Radio Canada. January 2013 : <http://www.youtube.com/watch?v=VOgnnqsxEU0>

« Du mauvais usage des brevets, ou comment contrôler la concurrence ». 30 minutes interview for *Les publications universitaires*, aired on Canal Savoir, November 2012. <http://www.publications-universitaires.qc.ca/?p=979>